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Abstract 
Diabetes is a common chronic disease with growing prevalence in Finland like worldwide. It 
shortens the life expectancy and the quality of life. Despite the development in medication and 
devices there has been only modest improvement in the outcome, especially among type 1 diabetic 
patients. 
The aim of this study was to compare the outcome of overall diabetes care in municipalities with 
different primary health care models of organising the follow-up of type 1 diabetes and type 2 
diabetes with special treatment problems. The study also aimed at estimating the feasibility of 
various indicators of the standard of diabetes care. 
The outcome, use and costs of health services connected with diabetes and its complications were 
compared in two suburban communities, Kouvola and Nurmijärvi. In Kouvola the follow-up of all 
patients had been based on family doctors already over 15 years whereas in Nurmijärvi the follow-
up of T1D patients and the complicated T2D patients had been centralized to 1-2 doctors for the 
same time. The diabetic populations of these municipalities resembled each other. 
In the centralized system T1D became cheaper for the municipality. Differences in the quality 
parameters were minor. Both these results were obviously due to more consultations of the 
specialist level in Kouvola. However, T1D patients were significantly more satisfied with the 
centralized follow-up model. 
In conclusion, the centralized follow-up of the most demanding diabetes in PHC is cost-effective 
and results in high patient satisfaction. The centralized model is better in the follow-up of T1D but 
in T2D there were no differences between these two models.  
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1 Introduction 
The prevalence of diabetes is rapidly growing in most countries of the world, including Finland (1). 
This phenomenon is closely connected with obesity, sedentary life style and energy-rich western 
diet (2, 3). In Finland, the incidence of type 1 diabetes is the highest among all nations (4, 5). The 
basic underlying causes for diabetes mellitus are still unknown, but both genetic and environmental 
factors are involved in the pathogenesis (6-13). 
In Finland there have been national guidelines for diabetes care for many years including detailed 
instructions for diagnosis, treatment, treatment targets and follow-up of the patients (14). 
However, limited data exists to evaluate how different models of organising diabetes follow-up 
influence the quality, outcome and costs of diabetes care. 
Treatment of type 1 diabetes is demanding and different from the treatment of type 2 diabetes. 
The quality of type 1 diabetes care as assessed only by HbA1c values has not improved during the 
past decades and there is still a vast excess mortality of type 1 diabetic patients compared with the 
whole Finnish population (15, 16-18). 
Physicians do not become very experienced in type 1 diabetes care if the number of diabetic 
patients on their responsibility is limited. Diabetes specialist nurses have traditionally supported 
the family doctors, but an experienced doctor as a team leader is valuable.  
This study tries to find answers to the question, if the centralized diabetes follow-up model in 
primary health care produces advantages to the society or to diabetic patients when compared 
with decentralized family doctor model.  This kind of evaluation requires feasible indicators of the 
quality of diabetes care.  Special attention is focused on the most traditional indicator, HbA1c.  Also 
the prevalence of hypoglycaemias is evaluated because of their connection to increased mortality 
in many recent studies (19, 20). 
Two municipalities with long histories of different models of diabetes follow-up in PHC were found 
for comparison. In Kouvola, the whole population had a family doctor who was determined by the 
residence address of the inhabitant. Every diabetic patient also had a family doctor according to 
this system. In Nurmijärvi, all type 1 diabetic patients and type 2 diabetic patients with special 
treatment problems were centralized to the follow-up of 1-2 physicians especially interested and 
trained in diabetes care. The diabetic populations of these municipalities were nearly same-sized. 
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2 Review of the literature 
2.1  Types of diabetes 
Diabetes is a group of diseases with elevated plasma glucose as a common feature. Hyperglycaemia 
leads to similar organ complications irrespective the reasons behind the elevated glucose levels 
(Table 1). 
Type 1 diabetes (ICD-10 dg: E10) is an immunologic disease which originates from the destruction 
of the insulin producing β-cells of the pancreas (10). The reasons for this disease are under vigorous 
investigation but still much is unknown. Both a genetic tendency and some triggering factor are 
probably needed (7, 8, 11-13). Insulin replacement is required in the therapy of type 1 diabetes. In 
Finland, about half of all type 1 diabetic patients get the disease before the age of 15 years (4). In 
the Finnish population, the incidence of type 1 diabetes is higher than anywhere else in the world. 
A subtype of type 1 diabetes with slow progression in adult age is called LADA (latent autoimmune 
diabetes in adults) (21). 
A typical feature of type 2 diabetes (ICD 10 dg: E11) is the reduced sensitivity of tissues to insulin 
(insulin resistance). During years or decades, worsening relative lack of insulin will develop leading 
to the need for insulin therapy. The lazy western lifestyle with too much food and too little exercise 
has been accused for the growing incidence of this disease, but there are also many risk genes 
increasing its probability (22, 23). This disease typically appears in middle-age or later, but currently 
it is met even among the school-aged children.  
MODY-diabetes (Maturity Onset Diabetes in Young, ICD-10 dg: E13) is a single gene disease, which 
is diagnosed at young age, mostly before the age of 25 years. In Finland 2-4 % of all diabetic 
patients are estimated to have MODY-diabetes. There are currently about ten known subtypes of 
MODY. They are dominantly inherited in autosomal chromosomes but there are also new 
mutations without the same kind of diabetes in previous generations (24). These patients are 
usually very sensitive to insulin therapy and prone to hypoglycaemic episodes. They may have 
lowered insulin production or changes in the normal regulation of insulin secretion (25).  
About 10 % of Finnish pregnant women have gestational diabetes mellitus (GDM; ICD-10 dg: 
O24.4), which means that diabetes is diagnosed the first time during pregnancy. It usually 
disappears after delivery, but the patient has an increased risk for later type 2 or type 1 diabetes, 
especially if she remains overweight (26, 27). 
 
12 
 
Table 1.  Comparison of the two main types of diabetes (types 1 and 2) 
 
 Type 1 diabetes Type 2 diabetes 
Number of 
patients in 
Finland 
 40 000  300 000 
Aetiology Immunological process; 
usually caused by genetic 
susceptibility in addition to 
some environmental factor 
Insulin resistance + beta cell 
apoptosis;  usually connected 
with risk genes, overweight 
and sedentary life style 
Heritability 2 – 6 % 40 (one of the parents) – 70 % 
(both parents) 
Age at the 
time of 
diagnosis 
50 % of cases under the age 
of 15 years, possible  even 
in old age 
Usually > 40 years of age, 
possible even in the school 
age 
Principles 
of the 
treatment 
of the 
glucose 
balance 
Insulin replacement therapy 
mandatory due to total 
insufficiency of own insulin 
production 
Depends on the severity of 
the disease: life style changes 
and oral hyperglycaemic 
agents,  insulin, GLP-1 -
agonists 
Connection 
to other 
diseases 
Risk of other  autoimmune 
diseases is increased 
Part of the metabolic 
syndrome in 80 % of cases 
Prognosis Shortens significantly the 
life expectancy (excess 
mortality especially to 
cardiovascular diseases) 
Morbidity to cardiovascular 
diseases 2-4 fold compared 
with the population on 
average 
Target of 
the 
treatment 
Good glucose control without risk of hypoglycaemias. Efficient 
treatment of all risk factors of cardiovascular complications including 
hypertension and dyslipidaemia. Changes towards healthier life 
style. 
 
There are also several reasons for secondary diabetes (ICD-10 dg: E13) that is caused by some other 
disease or medication or a disease of the pancreas. The pancreas can be resected due to a trauma 
or a tumour, thus causing diabetes. The most common reasons for pancreatitis are alcohol abuse 
and stones in the gall ducts. Other diseases causing secondary diabetes are Cushing´s disease, 
acromegaly and hemochromatosis. Common drugs behind secondary diabetes are glucocorticoids 
that stimulate gluconeogenesis in the liver and impair insulin sensitivity.  The risk of diabetes is also 
increased by other commonly used drugs like beta-blockers, diuretics and statins (28). 
There are still some rare diabetes types not mentioned above and some diabetic patients, whose 
disease is difficult to fit in any of these categories. New gene mutations leading to diabetes will 
surely be discovered.  
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2.2  Epidemiology of diabetes 
The prevalence of type 2 diabetes is growing almost everywhere in the world. About 10 % of the 
adult population in the developed countries has the disease (1). There are over 40 000 type 1 and 
over 300 000 diagnosed type 2 diabetic patients in Finland, with a population of about 5.4 million 
people (4, 29). It is also estimated that there are still at least 200 000 type 2 diabetic patients with 
an undiagnosed disease (29). These numbers are naturally approximations and are based on D2D 
study from the first half of the previous decade.  There are, however, no clear reasons to believe, 
that the situation would have significantly changed. Another prediction is that the prevalence of 
type 2 diabetes may still double during the next 10-15 years (14). The incidence of type 1 diabetes 
has nearly doubled between the years 1988 and 2006 and is now about 62 new cases per 100 000 
children under the age of 15 years. However, after the year 2006 the occurrence of new cases 
seems to have stabilized – at least for a period of five years (Figure 1). 
 
 
Figure 1.  The incidence of type 1 diabetes in children under 15 years of age in Finland (cases per 
100 000 children). Modified from Harjutsalo et al. 2013 
2.3 Organization and resources of diabetes care 
The Finnish public health care has traditionally been divided strictly to primary health care (PHC) 
and hospital based specialist care. The latter has been given in local, central and university hospitals 
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and their outpatient clinics. Diabetes is one of the most common and clearly the most expensive of 
our chronic diseases (29, 30). Most general practitioners working in PHC get some experience on 
the treatment and follow-up of diabetic patients in their practice. Only some of the most 
complicated type 2 diabetic patients are subject to regular consultation in hospital outpatient 
clinics. 
In Finland, the proportion of type 1 diabetic patients followed-up in PHC varies in a large scale: in 
some places, the type 1 diabetic patients in PHC are gathered to GPs especially interested and 
educated in diabetes care. Elsewhere their follow-up can be scattered to family doctors just 
depending on the home addresses of the patients. Diabetes specialist nurses follow diabetic 
patients in some municipalities; elsewhere all diabetic patients in PHC may be in the care of team 
nurses who have also many other duties in their work. Regional diabetes centres with 
multiprofessional teams are currently established in some larger cities. They are not as vulnerable 
as smaller units, but they demand a population large and dense enough. So, the quality of care is 
not equal to all type 1 diabetic patients, and there may also be big differences between the costs 
and cost-effectiveness of various organization models. 
In California Ho et al. (31) compared the outcome of diabetes care given by the physicians of a 
diabetes clinic versus a general practice clinic. According to this study recording of patients´ self-
monitoring of blood glucose levels, foot examination, comprehensive eye examination, HbA1c 
measurement, and referral to diabetic education took place more often in the diabetes clinic than 
in the general practice clinic. 
The cost-effectiveness of diabetes care given by physicians versus diabetes oriented nurses has 
been compared in a short trial in the Netherlands with the conclusion that there were no 
differences between the results provided by the study groups (32). The influence of different 
working arrangements of diabetes specialist nurses to the treatment results of diabetic patients has 
been studied e.g. in Sweden (33). The results showed that organizing the care of type 2 diabetes in 
a structured way encourages better metabolic control in spite of less use of oral medication. The 
knowledge of the disease among the patients was better and the self-management more active 
thus favouring the implementation of local guidelines.  
Overall, it has been shown that more PHC resourcing is associated with reduced hospitalisation in 
chronic diseases (34). However, the resourcing must be kept within sensible limits and the 
organization in PHC has to be as effective as possible. 
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2.4 Treatment principles of diabetes 
Type 1 diabetes is a disease with insufficient own insulin production of the pancreas caused by an 
immunological process against the insulin producing β-cell mass. Total insulin deficiency leads to 
death in a few days. The treatment is based on insulin replacement therapy. The patient takes 
usually long-acting insulin analogue as injections once or twice daily and rapid-acting insulin with 
meals imitating the actions of a healthy pancreas (multiple daily injections, MDI). Alternatively 
rapid- or short-acting insulin is continuously infused subcutaneously with an insulin pump. The 
basal doses of insulin used in the pump are tailored according to an individual glucose profile and 
usually 2-4 different insulin infusion rates are used during 24 hours (35, 36). If needed, the patient 
can make temporary changes to the basal profile and the sizes of the meal insulin doses must be 
decided by the patient. Oral medications against hyperglycaemia are used only exceptionally in 
pure type 1 diabetes.  
An important part of the treatment of type 2 diabetes is the correction of lifestyle factors. In 
practice, this means an increase in the amount of exercising and efforts to reduce overweight by 
healthy dietary changes. Optimally changes in the lifestyle are more efficient in the treatment of 
type 2 diabetes than any single drug alone. Medical treatment of hyperglycaemia in type 2 diabetes 
is dependent of the duration and the severity of the disease. The lack of insulin is usually only 
relative and worsens during the course of time. The amount of insulin in blood and tissues may be 
even higher than normal but its efficacy has decreased. The target of the treatment is to increase 
the amount of insulin in the organ system or to improve the insulin sensitivity of the tissues. The 
drugs may also increase glucose excretion through the kidneys (SGLT2-inhibitors) or decrease the 
amount of gluconeogenesis in the liver (Table 2). The choice of the treatment depends on the 
residual insulin secretion capacity, the function of kidneys, the age, weight, occupation and the 
overall capacity of the patient. The means and goals of the treatment of a type 2 diabetic patient 
are highly individualized.  The first-line drug at the time of diagnosis in type 2 diabetes is metformin 
with only a few exceptions like severe renal insufficiency or alcoholism (37, 38). In the long run 
insulin becomes mandatory when the β-cell impairment has proceeded.  
To decrease the amount of complications and the high risks of premature death in diabetic 
populations, it is very important to take efficient care of all risk factors for the vascular diseases in 
the treatment of both diabetes types (39, 40). The risks to developing diabetic complications have 
lowered significantly during the latest decades in the US and also in Finland (41, 42). The reasons 
and their relative proportions for this positive development are still speculative, but the disease 
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burden has not lightened because of the rapidly growing total number of new diabetic patients. 
The treatment of hyperglycaemia should not lead to a marked risk of hypoglycaemia (43-45). 
 
Table 2. The mechanisms of the influences of drugs used in the treatment of glycaemia in type 2 
diabetes 
Mechanism Drug classes 
Insulin secretageous Sulphonylureas 
DPP4-inhibitors 
GLP1-analogues 
Insulin sensitizing Thiazolidinediones 
Glucosuric SGLT2-inhibitors 
Insulin replacement Insulins 
 
 
2.5 Long-term complications of diabetes 
2.5.1 Microvascular complications (retinopathy, neuropathy and nephropathy) 
The risk of diabetic microvascular complications increases with worsening glycaemic control (45, 
46). The level of the risk is, however, not in straight correlation to the average glucose 
concentration. There are genetic factors that either protect against complications or increase the 
risk. In type 1 diabetes the FinnDiane Study Group has especially studied the genetic factors 
predisposing to nephropathy and retinopathy (47). Concerning to type 2 diabetes, 40 genes have 
already been found that predispose the diabetic patient to the disease and give an explanation to 
the varying clinical expression and risk profile of complications (22).   
Small arteries also suffer from hyperglycaemia that gradually causes damage in neural tissues, 
retina and kidneys, especially in genetically prone diabetic people. The risk of all vascular 
complications increases with arterial hypertension and dyslipidemia and smoking. Sufficient results 
have not been achieved by the treatment of hyperglycaemia alone. For these reasons the goal in 
the care of diabetes is to get all the risk factors into optimal control. 
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The prevalence of diabetic retinopathy increases with the duration of the disease. In type 1 
diabetes about 90 % of all patients have at least slight background retinopathy after 20 years of the 
disease.  About one third of type 2 diabetic patients have clinical findings of retinopathy already at 
the time of diagnosis (48). This means that they have had undiagnosed diabetes for several years. 
Eye fundus photographing aims to early detection of diabetic eye complications and to their 
treatment in proper time. The recommended time interval between the consecutive imaging of the 
eyes is maximally two years in type 1 and three years in type 2 diabetes (49). For diabetes in the 
pregnancy there are special guidelines (50). The eye complications are usually treated with laser-
coagulation, intrabulbar injections or vitreal surgery, depending on the degree of the eye damage.  
At least one third of type 1 diabetic patients have the first signs of nephropathy after 20 years of 
the disease. Currently, however, the incidence of new dialysis therapies connected to type 2 
diabetes has exceeded the incidence of new dialyses patients in type 1 diabetes in Finland. Early 
detection is important also in diabetic nephropathy. The screening of nephropathy is based on 
measuring nocturnal albumin excretion yearly from the urine.  In Finland, in type 1 diabetes the 
screening is recommended yearly after five years from the beginning of the disease (14, 51). 
Constant microalbuminuria is one criterion for the diagnosis of diabetic nephropathy but the 
disease can develop also without early albuminuria (52, 53). The careful follow-up and strict control 
of blood pressure are essential in slowing down the progression of renal insufficiency. The first-line 
choices of antihypertensive medication are angiotensin receptor blockers or inhibitors of the 
angiotensin converting enzyme (46).  
Some signs of diabetic neuropathy develop into practically every diabetic patient in the course of 
years. Like retinopathy it is common already in the phase of diagnosis of type 2 diabetes. The 
symptoms and clinical findings of diabetic neuropathy are multiform. The diagnosis in PHC is usually 
done by examining the feet of the patient: the sense of touch with a monofilament and the sense 
of vibration with a tuning fork (128 Hz) should be tested from every diabetic patient at least yearly. 
The treatment of neuropathy is mostly symptomatic. The use of alcohol must be as restricted as 
possible, because alcohol and hyperglycaemia have additive negative influence on the neural 
tissue. Other possible causes of neuropathy, like hypothyreosis and B12-vitamin deficiency, must 
naturally be checked and treated when diagnosed. 
The glycaemic control and the blood pressure must be checked and optimized, and the possible 
smoking ceased latest at the time of the first signs of microvascular complications. The follow-up 
studies of UKPDS and DCCT show that the difference in HbA1c values between the intensive and 
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standard care groups vanishes during 1-2 years after the cessation of the actual trial phase (54, 55). 
Good results in the care of hyperglycaemia do not keep without continual efforts.  
2.5.2 Macrovascular complications 
About 60% of all deaths of type 2 diabetic patients in Finland are due to cardiovascular diseases, 
while the proportion in the whole population is about 40% (15, 56). The excess mortality among the 
type 2 diabetic population has, however, decreased during the last decades (15). Unfortunately, 
this positive development does not concern type 1 diabetic patients (15). Diabetes increases the 
risk of atherosclerosis regardless of the type of the disease. Its clinical manifestations are coronary 
heart disease, stroke and peripheral vascular disease contributing partly to the ´diabetic foot´. The 
relative risk for the arterial disease in working age is about 4 times in men and even 8 times in 
women with type 1 diabetes compared with all Finnish men and women of the same age. In type 2 
diabetes, the risk ratio is about 2-4 but still very significant (15). 
Smoking is still more common among type 1 diabetic patients than in the overall Finnish 
population. Smoking cessation is very important in the prevention of macrovascular complications. 
Hypertension and dyslipidemias are also more common in the diabetic population than in the non-
diabetic population and they contribute to the increased risk of vascular diseases.  
2.5.2 Diabetic foot 
Hyperglycaemia causes glycosylation of many protein-based structures in the organ system. This 
phenomenon causes the reduced mobility of joints and elasticity of tendons and ligaments and is 
partly underlying the slow formation of the diabetic foot with a high arch and hammer toes (57). 
Glycosylation of proteins influences on the organ system in many ways increasing e.g. the risk of 
the ´frozen shoulder´ and the ´carpal canal syndrome´. On the whole, the diabetic foot is a complex 
combination of many pathological mechanisms related to chronic hyperglycaemia. Sensomotor 
neuropathy weakens the position sensing and causes numbness of the foot thus exposing the skin 
to wounds and abrasions. The balance of small muscles changes and all these together lead to 
alterations in the way of walking. This change in turn predisposes the sole to the formation of local 
thickening. Autonomic neuropathy causes reduction of sweating and dries the skin, which in turn is 
a partial cause to wounds that are prone to bacterial and fungal infections in hyperglycaemic 
surroundings with reduced arterial circulation. The peripheral infections are often very resistant to 
antibiotic therapy because of the weakened local immunological response due to the impaired 
blood flow (58). 
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2.6 Acute complications 
2.6.1 Ketoacidosis and symptomatic hyperglycaemia 
Diabetic ketoasidosis is caused by nearly total lack of insulin. Insulin deficiency increases lipolysis 
from the adipose tissue and free fatty acids (FFA) are used as a major fuel of metabolism. The 
incomplete burning of FFA produces a cumulative amount of ketone acids, which lower the pH of 
the blood. The metabolic disorder results in ketoacidosis when the pH of the blood is less than 7.30. 
Ketoacidosis is a life-threatening situation and requires urgent emergency care (59). 
A subset of type 1 diabetic patients has ketoacidosis at the time of diagnosis. Later in the course of 
type 1 diabetes ketoacidosis may develop if the patient for some reason is left without insulin. 
Alcohol use and psychiatric disorders are obviously the main reasons why type 1 diabetic patients 
neglect their insulin injections. A severe infection can be a contributory factor by causing temporary 
insulin resistance. Theoretically a type 1 diabetic patient with insulin pump therapy has higher risk 
to ketoacidosis, because the pump usually contains only rapid-acting insulin with a small 
subcutaneous insulin reservoir. A disruption in the insulin dosing can lead to ketoacidosis already in 
a few hours if the patient does not notice the situation in due time. Insulin damaged e.g. by heath 
or frost can also cause ketoacidosis. The symptoms of diabetic ketoacidosis are nausea, pains in the 
chest and the stomach, shortness of breath (hyperventilation) and a decreasing level of 
consciousness. Ketoacidosis can develop without marked hyperglycaemia. There were 15 cases of 
death because of ketoacidosis in the year 2012 in Finland according to the Statistics Finland. Of the 
cases 11 were males and 4 females (60). 
Hyperosmotic nonketotic coma can develop gradually in type 2 diabetes with a relative insulin 
deficiency, often during an infection. The hyperglycaemia causes a hyperosmotic situation with 
symptoms like somnolence and may gradually decrease the level of consciousness. The blood 
glucose concentration is usually very high, between 30 -100 mmol/l. This situation is very rare but 
severe with the death rate ranging from 20 to 50 % (59, 61). 
Lactic acidosis may develop in patients with metformin use, especially connected with alcohol 
consumption and in renal insufficiency. Metformin use should be ceased in case of serious renal 
insufficiency and acute situations causing the risk of dehydration or ischaemia (38). 
 2.6.2    Incidence and significance of hypoglycaemias 
Hypoglycaemia is principally determined as a situation where the plasma glucose concentration is 
less than 4.0 mmol/l. The hypoglycaemia is called symptomatic if the low plasma glucose value is 
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associated with hypoglycaemic symptoms (Table 3). First the symptoms are adrenergic consisting of 
tremor, sweating, palpitation and dyspnoea and in the next phase neuroglycopenic symptoms like 
inertia, sight disturbances, blurred speech and tiredness may dominate (62, 63).  Hypoglycaemia 
may be totally asymptomatic if the counter regulatory response has vanished. Hypoglycaemia is 
usually classified severe, if the patient needs help from other people to recover (43).  A patient, 
who is used to very high plasma glucose concentrations, may have typical hypoglycaemic symptoms 
if the P-glucose decreases rapidly from high to normal values. Thus the organ system recognises 
better the changing glucose level than the absolute number (64). 
 
Table 3. Typical symptoms of hypoglycaemia in relation to plasma glucose concentration 
P-glucose  Symptoms of hypoglycaemia 
sympatoadrenergic  / kolinergic                         neuroglycopenic 
2,5 – 4,0 mmol/l palpitation, tremor, 
anxiety/euphoria 
hunger, sweating, disturbances 
of sensing 
 
˂ 2,5 mmol/l  weakening of judgement, 
visual disturbances, tiredness, 
blurred speech, aggression, 
consciousness 
 
Hypoglycaemias are almost inevitably connected to insulin treatment. However sulphonylurea 
treatment may also result in hypoglycaemia, especially when the patient has renal impairment. 
Almost all insulin treated diabetic patients have hypoglycaemias. Slight hypoglycaemic symptoms 
may happen several times a week in the life of a type 1 diabetic patient. There are some 
anamnestic features that are usually connected with a high risk of severe hypoglycaemias like long 
diabetes duration, hypoglycaemia unawareness, and strict glycaemic control, previous SH episodes 
and male gender (65-68). 
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In the DCCT trial, the incidence of serious hypoglycaemias (SH) was 61.2 episodes per 100 patient-
years in type 1 diabetic patients with intensive insulin therapy (69).  In insulin pump therapy, the 
incidence of SH seems to be lower than in MDI-therapy and continuous glucose monitoring (CGM) 
obviously still reduces the risk (70-74). At the same time the price of the care increases and the 
influence on the long-term cost-effectiveness still needs more studies.  
The risk for hypoglycaemia has previously thought to be lower in type 2 diabetes and the estimates 
vary in a large scale. In retrospective studies, the incidence of SH in insulin-treated type 2 diabetic 
patients has been between 15 and 73 episodes per 100 patient years. In prospective studies, the 
incidence has been lower, probably because of the exclusion criteria in randomised controlled trials 
(75).  
SHs carry much significance for diabetic patients. An acute SH may cause accidents and injuries. In 
old patients SHs increase the risk of cardiovascular events, mostly by activating antagonistic 
hormonal reactions. It has been estimated that even 10% of the deaths of type 1 diabetic patients 
are caused by hypoglycaemia (76). Recent studies also prove a connection between SHs and 
dementia or lowering of cognitive functions (77, 78). Even one SH can be the reason for a life-long 
fear that ruins the possibilities to good glucose balance for the rest of the life (79-82). 
The economic burden of hypoglycaemias to the society comes partly from the use of emergency 
health care but mainly from the disability to work: sick days and lowered efficacy after the episode 
(83-86). Only the top of the iceberg is seen in the emergency rooms of hospitals: no more than 
about 30% of all SHs are treated by health care professionals and, e.g. in Helsinki, 89.9% of these 
patients got the treatment by the paramedics without transferring to hospital (86). Thus, only 3% of 
all SHs can be found in the Finnish Hospital Care Register HILMO; however, probably the majority of 
the most serious episodes (87).  
Recent observations based on big study populations (ACCORD, ADVANCE, VADT) have led to new 
estimations for the HbA1c goals in recommendations for the care of diabetes (14, 88, 89). Low levels 
should be aimed at only when the risk of SHs is tolerable. The goals are now individual and are 
influenced by the age, occupation and renal function (14). On average, lower HbA1c levels correlate 
with lower risk of diabetic complications, but high visit-to-visit variability of HbA1c and fasting 
plasma glucose also seem to be predictive of adverse outcomes (90). 
2.6.2 Hypoglycaemias and permission to drive 
While driving a vehicle, hypoglycaemias always carry a marked risk of the health and safety of both 
the diabetic patient and other people in the traffic. The risk of insulin-treated diabetic patients to 
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traffic accidents has been showed to be higher than the risk of the rest of the population (91-96). 
Moreover, not only hypoglycaemias, but also high levels of plasma glucose decrease the cognitive 
capacity of the patient by causing somnolence and decreasing alertness. The European and Finnish 
regulations for diabetes and driving emphasize the role of hypoglycaemias and the motivation of 
the diabetic driver to measure her/his blood glucose always before the beginning of driving and 
every second or third hour of a prolonged driving session (97, 98). In Denmark the reporting of SHs 
by type 1 diabetic patients reduced by 55% when the new regulations were implemented and the 
proportion of the patients reporting of recurrent SHs decreased from 5.6% to 1.5% (99). The 
conclusion of the writers was that the new regulations may paradoxically weaken the safety in the 
traffic. SHs always cause a need for reanalysing the care of a diabetic patient and at least the 
reason for the episodes must be reconstructed. In case of driving heavy vehicles or in occupational 
driving, even slight hypoglycaemia induced changes in the level of consciousness are not allowed. 
Driving performance may be especially difficult to judge in the insulin-treated diabetic drivers with 
hypoglycaemia unawareness. 
2.7 Use and costs of health services of diabetic patients 
Kangas has calculated the costs of diabetes care in Finland (100). According to his data, diabetes 
with its complications was by far the most expensive chronic disease for the Finnish health care 
system already in the year 1989. The direct costs of diabetes care were in total 5.8 % of the health 
care costs of the whole Finnish population. In that time, the proportion of drug-treated diabetic 
patients was 1.9 % of the total population. 18 years later (year 2007) the proportion of the costs of 
diabetes care was 8.9% of the total health care expenses, but the method of calculation was slightly 
different (101). In an estimation of the global expenditure of diabetes care 12% of total health care 
costs were used in diabetes care in the year 2010 (102). The study covered people aged 20-79 years 
in 91 countries where appropriate data was available. 
After the year 1989 the number of diabetic patients has more than doubled but fortunately the 
costs have not increased so fast (100, 101). This is probably due to the increasing proportion of 
newly diagnosed type 2 diabetic patients. Diabetes with complications is many times more 
expensive for the society than diabetes without complications (100, 101). This also emphasizes the 
fact that effective diabetes care from the early diagnosis is very important in order to postpone or 
avoid the development of expensive complications.  
 
 
23 
 
2.8 Outcome and quality of diabetes care 
2.8.1 Glycaemic control of T1 and T2 diabetic patients in Finland 
Valle et al. (16-18) have analysed the quality of diabetes care in Finland three times with the 
intervals of about eight years (1993, 2000-2001 and 2009-2010). The cross-sectional study was 
performed with the same principles each time in order to get comparable results. The target was to 
get the data of 50 consecutive diabetic patients (per care unit) over 15-year-old visiting outpatient 
clinics for routine diabetes follow-up. These studies are based on samples and questionnaires 
directed to hospitals and health care centres. An arrangement like this is susceptible to a selection 
bias. However, they form our best knowledge of the present-day situation in the care of the 
glycaemic control and other markers of diabetes care in Finland. The HbA1c values were measured 
in local laboratories using varying HbA1c assays. Differences in the distribution of HbA1c assays 
between cross-sectional studies may have significant effect on the results observed.  
 
Table 4. Cross-sectional quality of diabetes care in Finland between years 1993 and 2009-2010 as 
expressed by median values.  LDL = LDL-cholesterol, BP = blood pressure, BMI = body mass index.  
Modified from Valle et al. 1997-2010 
 Type 1 diabetes Type 2 diabetes 
Year 1993 2000-2001 2009-2010 1993 2000-2001 2009-2010 
Patients n. 599 925 963 1165 1961 2058 
HbA1c, % 8,6 8,5 8,4 8,6 7,6 6,7 
LDL, mmol/l  2,7 2,4  3,1 2,4 
BP, mmHg  130/80 136/80  150/84 142/81 
BMI, kg/m2 25,0 24,6 25,1 29,0 29,3 30,2 
 
In Valle´s studies the median of HbA1c values in type 2 diabetes has lowered and was 6.7% during 
2009-2010 (Table 4). The glycaemic control in type 1 diabetes patients has not, however, changed 
over the observation period of 16 years: the median stays on the level of about 8.5%. 
2.8.2 Body mass index, blood pressure and LDL-cholesterol of type1 and type 2 diabetic patients in 
Finland 
The median body mass index (BMI) is increasing in patients with type 2 diabetes from 1993 to years 
2009-2010 (Table 4). Also the median blood pressure of type 1 diabetic patients has developed in 
the wrong direction. 
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2.8.3 Screening of microvascular diabetic complications 
The eye fundus photographs had been taken In Finnish health care centres from 60.3% of all type 2 
diabetic patients during the past two years in the year 2005. In most municipalities, this service is 
bought from private companies. Nocturnal albuminuria had been analysed from 42.2% of type 2 
diabetic patients during the preceding year (Klas Winell, Finnish Quality Network, personal 
information). The corresponding data of type 1 diabetic patients in Finland is not available. The 
data of type 2 diabetic patients is based largely on patients at pre-planned visits in dedicated health 
care centres. The results may therefore be better than in the reality. The data of FQN is not 
published in peer reviewed scientific journals for critical evaluation. It is, however, the best 
available data of the treatment balance of Finnish type 2 diabetic patients. 
2.9  Significance of the outcome of care for the diabetic patient and for the society 
UKPDS proved in type 2 diabetes and DCCT in type 1 diabetes that a stricter glycaemic control 
reduces significantly the risk of microvascular and also slightly the macrovascular diabetic 
complications (103-105). The post-trial monitoring of both studies, however, showed that the 
intensive treatment group could not maintain the good glycaemic control achieved during the trial 
(54, 55): after the more active follow-up had ceased, the difference in HbA1c between the 
conventional and intensive care groups was rapidly lost. However, the incidence of new diabetic 
complications remained significantly lower during the whole post-trial follow-up of ten years in 
type 2 diabetic patients with intensive treatment during the trial period (106). This phenomenon, 
called the ´metabolic memory´ or the ´legacy effect`, suggests that even a short period of good 
glycaemic control may have a long lasting effect on the incidence of diabetic complications.  
According to recent statistics, type 1 diabetic patients, who have not developed microalbuminuria 
during the first 15 years of their disease, have a life expectancy comparable with the general 
population (107). The concept of metabolic memory was also detected in the follow-up trial (EDIC) 
of type 1 diabetic patients primarily included in DCCT. The incidence of microvascular complications 
remained still smaller in type 1 diabetic patients with intensive therapy during DCCT although the 
difference in the glycaemic control between the study groups was lost after the end of DCCT (55).  
A multifactorial approach with an intensive treatment of all known risk factors for diabetic 
complications has been emphasized during the recent years. Steno 2 trial proved the advantages of 
the simultaneous intensive therapy of hyperglycaemia, arterial hypertension and dyslipidemia (108-
111).  
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2.10 Measures to compare the outcome and quality of diabetes care between different care units 
The performance of diabetes care between various care units in Finland and in other countries has 
been tried to compare (31, 112-114). Because of the lack of national diabetes registers in most of 
the countries, the comparisons between different diabetes care providers have usually based on 
various-sized patient cohorts. This may create a selection bias between the study groups. Also the 
HbA1c determinations have not been done with the same standardized laboratory assay (112). 
Recent guidelines have also stressed the individualized goals of diabetes care as indicated by 
individual target HbA1c depending on the clinical features of the patient (14). Good glycaemic 
control cannot be judged only by HbA1c values but also other clinical factors as the number and 
degree of hypoglycaemias and control of other cardiovascular risk factors (LDL-cholesterol, blood 
pressure, smoking etc.) must be taken into account. Based on these facts, the comparative studies 
using only HbA1c -values as a measure of quality between different diabetes care units, may not be 
very informative (112, 114). In North Carelia, Finland, the quality comparison of diabetes care 
between the municipalities of the area has been brought forward: the whole area operates with 
the same data system, uses the same laboratory and has a covering patient register (115). 
However, in Finland there is still neither a national indicator definition nor a follow-up system of 
the indicators – opposite to the UK, the United States, Australia and Sweden (116-119). 
In diabetic populations there are usually about 10-20% of the patients who are outliers of contacts 
to the organized diabetes care system. These diabetic patients renew their drug prescriptions 
without a direct contact with the personnel. They are supposed to have mostly unsatisfying glucose 
control and an increased risk developing both acute and chronic diabetic complications. The 
coverage of regular diabetes follow-up among the diabetic population could maybe be used as one 
marker of good quality, too. 
There are many guidelines and recommendations for the care of diabetes, both on national and 
international level (14, 120-122). Small differences in these alignments may exist, but the main 
principles are usually similar. One indicator for the good quality of diabetes care – at least at 
national level – could be the implementation of the current recommendations (123). 
´Soft measures´ to evaluate the quality of diabetes care should include the satisfaction and quality 
of life of the patients by using questionnaires especially targeted for diabetic patients. Previous 
studies have shown that diabetic patients are usually satisfied with their diabetes care if they think 
that the technical level of the care is high (124). Young type 1 diabetic patients in Ireland were 
satisfied with their diabetes care, even where they noted that aspects of those services were sub-
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optimal (125). The results of diabetes care also seem to depend on the communication skills of the 
physician (126).  
The costs and the cost-effectiveness of care have become more and more important issues during 
the past decades in the health politics of the society. The equally high-quality diabetes services 
have to be produced for all diabetic patients with limited expenses. At the same time the 
proportion of old people and the total number of diabetic patients are steadily growing and the 
possibilities to efficient, but often expensive new treatments are increasing. Thus the comparison 
of the quality of care in two health care units demands that the cost-effectiveness of the diabetes 
care models is also evaluated. The means for cost analysis have now improved with the DRG-based 
invoicing of the municipalities by the secondary and tertiary care units (including both inpatient and 
outpatient care) and the APR-based knowledge of the consistence of PHC visits (127, 128). The 
diagnoses for inpatient care periods are gathered and saved to the national HILMO-register on all 
levels of care and in the near future this will cover all of the outpatient visits. Methods of 
comparing the quality of diabetes care are summarized in Figure 2.   
 
Figure 2. Indicators for the comparison of the quality of diabetes care. 
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3 Aims of the study 
The aim of the study was to assess whether the model of diabetes care in PHC (centralized or 
decentralized) has an effect on the quality of care, glycaemic control, diabetic complications, 
specialist consultations, use of hospital beds and overall health care costs in diabetic patients living 
in two municipalities with different organizations of diabetes care.  
Special attention was paid to type 1 diabetes and: 
I Quality indicators, especially HbA1c (study I) 
 
II Incidence of observed serious hypoglycaemias (study II) 
 
III Influence of serious hypoglycaemias on driver´s licence holding (study III)   
 
IV Quality and costs of diabetes health care (study IV) 
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4 Patients and methods 
4.1 Selection of the municipalities compared 
Two municipalities with different organisations of diabetes care were selected for the comparison: 
1.  In Nurmijärvi, the diabetes care has been organized in the centralized model already for over 20 
years. There have been 1 – 2 doctors with the responsibility of diabetes care during these years. 
Nurmijärvi is a growing municipality with 35922 inhabitants at the end of the year 2003 (39018 at 
the end of the year 2008) bordering the Finnish capital region from the north. There is no single city 
centre but three smaller population centres. The rest of the municipality is countryside and a 
marked proportion of the population belongs to old local families. Most of the immigrants are 
native Finnish families, whose parents work in the capital region. They search for more space for 
living with a lower housing price and safer surroundings for their children. The average age of the 
population in Nurmijärvi is low and the average educational level high. 
2.  In Kouvola, the diabetes care has been organized in the decentralized model based on family 
doctors for over 15 years. Kouvola was a town of nearly equal size with 31399 inhabitants at the 
end of the year 2003 (30633 at the end of the year 2008) and at the beginning of the study design. 
In the beginning of year 2009 it was fused with five other neighbouring municipalities. In this 
presentation ´Kouvola´ means the old Kouvola, where the diabetes care in PHC has been arranged 
in a decentralized model since the early 1990´s. The old Kouvola is located in the middle of an area 
of wood processing industry. It is also a node of railway-traffic. Typically, the workers of the 
factories have lived in the neighbouring municipalities and the white-collar people in the town of 
Kouvola. The population of Kouvola is decreasing due to structural changes in industry. Kouvola and 
Nurmijärvi were chosen for comparison because of many mutual features in these municipalities. In 
both health care centres there was also a covering register of the diabetic patients living in the 
municipality. 
4.2 Determination of the diabetic cohorts 
The study cohorts were determined in the same way in both municipalities. The customer lists of 
the public cost-free distribution points of diabetes care supplies were used to get the lists of 
diabetic patients. There are practically no diabetic patients who do not fetch their care supplies 
free of charge. The target populations consisted of all diabetic patients of Kouvola and Nurmijärvi 
who fulfilled the diagnostic criteria of diabetes mellitus and reached the age of 18 years by the end 
of the year 2004. This cohort was followed throughout the study (Figure 3). 
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Two diabetic populations as similar as possible were searched for the study. If possible, they would 
differ from each other just by the model of organization of diabetes care in PHC. Figure 3 shows the 
flow chart, how the numbers of the diabetic patients of these two municipalities were included in 
the studies. 
The most obvious difference between the populations of these two municipalities was the age 
structure: the proportion of people in working age was similar in both municipalities but there were 
more children in Nurmijärvi than in Kouvola: 25% vs.15% of the whole population was under the 
age of 16 years. On the other hand, the number of old people was higher in Kouvola than in 
Nurmijärvi (20% vs. 10% were in the age group over 64 years). This difference did not have any 
impact on the diabetic populations, which were nearly of the same age and the same size and had a 
similar duration of the diabetes. 1776 diabetic patients over 18 years of age and living either in 
Kouvola (951) or Nurmijärvi (827) were identified from the Reimbursement Register of the Social 
Insurance Institution of Finland (KELA). They were eligible for reimbursement for antidiabetic 
medication. However, the number of diabetic patients over 18 years of age using the public free-of-
charge distribution points of diabetes care supplies was much bigger: 1195 patients in Kouvola and 
1170 in Nurmijärvi, altogether 2365 patients. The big difference is caused by the fact that at the 
time of the beginning of the study KELA admitted the reimbursement for antihyperglycaemic 
medication only after half a year of regular medication use. At that time there were also many 
people with recently diagnosed diabetes who had only life style treatment with no medication, 
according to contemporary recommendations. They were, however, included in the study. Only the 
patients, who had returned the 36-item questionnaire, were included to the evaluation of severe 
hypoglycaemias. The anonymous register data of the use of health services was possible to be used 
of all the diabetic patients without separate permissions. Totally 16 patients denied the use of their 
health records (three of them at a later phase of the study) and they were excluded. 
The diabetes specialist nurses or the nurses in the distribution points for diabetes care supplies 
gave an information brochure of the study during four months in the year 2005 to every patient 
who fulfilled the criteria. If the patient admitted the use of her/his patient records in PHC and the 
specialist level, she/he was asked to sign an informed consent. If the patient was not present 
personally, she/he got the forms with the supplies and was asked to return the forms with the 
signature or comments in a closed envelope, the postal fee of which was paid in advance. 
The forms were posted to those diabetic patients of the target groups, who did not visit the 
distribution points during these four months. After one month, the same forms were posted still 
once more to those who had not yet responded to the first letter. The result of this last circuit was 
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not abundant – the exact number of questionnaires returned by different posting circuits was not 
recorded. The filling of the questionnaires was not superintended. The proportion of patients, who 
returned the questionnaire, was quite high, but the drug-treated patients of Nurmijärvi were more 
active than those of Kouvola (p < 0.001, Figure 3).   
                        
Figure 3. Recruitment of patients into the studies 
 
4.3 Data collected 
4.3.1 Background information of the patients 
All the patients in the target cohorts were asked to answer a 36-item questionnaire (Appendix I) 
about their background and lifestyle and many other issues related to diabetes.  It is shortened and 
modified from the avtk questionnaire of the National Institute for Health and Welfare with the 
permission of Professor Antti Uutela (129). The questionnaire included questions about the 
duration of diabetes, depressive symptoms, severe hypoglycaemias, smoking and alcohol use, 
amount of physical training and details of diet.  The background included the profession, education, 
marital status and housing conditions. 
31 
 
4.3.2 Blood samples for simultaneous HbA1c measurement in the laboratories used by the health 
centres of the study municipalities – Study I 
35 blood specimens of diabetic patients were divided for the simultaneous analysis of HbA1c in both 
laboratories used. This was done without any preceding notice to the laboratories, because the aim 
was to test the everyday routine analytics of HbA1c assays in both laboratories involved in the care 
of the diabetic patients of the study municipalities. The blood samples were taken in the 
laboratories of the two health centres into EDTA-vials without any pre-treatment according to the 
normal routines.  All samples were sent to the analysing laboratories by their regular customers. 
Both laboratories had immunological analysis methods standardised against the IFCC reference 
method. The results were turned to the DCCT level using a coefficient. The laboratory used by 
Kouvola had a Roche Integra 800 analyser and Roche´s reagents. The laboratory used by Nurmijärvi 
had Olympus´ analyser and reagents. 
4.3.3  Glycaemic control, LDL-cholesterol, blood pressure and body mass index of the patients and 
implication of the national guidelines for diabetes care – Study IV 
The means of HbA1c, LDL-cholesterol, blood pressure and body mass index were calculated 
categorised by diabetes type and a comparison was made between the study municipalities. 
Moreover, an analysis was done, how the recommendations of national guidelines for diabetes 
care were met. 
4.3.3 Incidence and risk factors of serious hypoglycaemias – Study II 
In the Reimbursement Register of the Social Insurance Institution of Finland, there were altogether 
1776 adult patients with reimbursed diabetes medication and living in the study municipalities at 
the end of the year 2003. Informed consent was obtained from 1437 of them (80.9%) to use their 
clinical data from different sources. The population for the analysis of self-reported severe 
hypoglycaemias consisted of those drug-treated patients who also filled and returned the 36-item 
questionnaire (n=1327).  686 of them had insulin treatment and were thus in the major focus of the 
study. All the patients were asked in the questionnaire if they had suffered from serious 
hypoglycaemias during the previous year (2005). If the answer was positive, they were asked to list 
the number of the hypoglycaemic episodes. 
A cohort of 1469 study patients with informed consent to use their medical data was cross checked 
from the local paramedic registers for the alarms made because of hypoglycaemia. This cohort 
included patients with informed consent and diet therapy. Moreover, the HILMO registers were 
screened in order to find severe hypoglycaemias, which had led to emergency room visits or 
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hospital care. The criterion for serious hypoglycaemia was the need for another person´s aid to 
recover from the disorder (43, 130). The patient records were screened in order to find possible risk 
factors for recurrent hypoglycaemias. 
4.3.4  Data of the driver´s licences of diabetic patients with recurrent serious hypoglycaemias – 
Study III 
The targets of interest included the influence of recurrent severe hypoglycaemias on the validity of 
driver´s licences of the diabetic patients. The validity of driver´s licences is public data in Finland 
and can be used freely without a separate permission. This data was collected with the assistance 
of traffic authorities in both municipalities. 
4.3.5 Use and costs of health care services of diabetic patients - Study IV 
The use of the health care services of diabetic patients was divided into two categories: to those 
resulting from diabetes itself or its known complications and to those caused by other medical 
reasons. 
The interest of the study was focused on the diabetes-related use of health care services (Appendix 
II). This data was collected from the years 2005-2010 from the National Hospital Discharge Register 
(HILMO) maintained by the Finnish National Institute for Health and Welfare. The HILMO register 
includes individual level data on inpatient care in PHC and private health care, as well as on all 
types of specialist care given in local, central and university hospitals.  Considering the outpatient 
care in PHC, the period of review was one year (2005) because this data could not be analysed 
automatically. The number of PHC outpatient visits was collected manually from electronic medical 
records by one nurse in Kouvola and one nurse in Nurmijärvi. These nurses were employees of the 
health care centres but did not work in diabetes teams. They received special training and similar 
instructions and calculated the amount of outpatient visits (to doctors and diabetes specialist 
nurses) whose main content was diabetes or its complications. These results were multiplied by six 
and corrected to the price level of year 2010 in the final analysis. 
The costs of diabetes care on secondary and tertiary level health care were the direct invoicing 
sums of the hospital outpatient visits and inpatient periods, based on DRG grouping. The visits in 
PHC were priced by using the APR prices counted for the diabetes care contacts of Kouvola health 
centre in the year 2009 (128).  
The especially expensive patients, whose costs exceeded 100 000 € during six study years, were 
excluded from the calculation and comparison of the average diabetes care costs. Of these six 
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patients, four lived in Nurmijärvi (three with type 1 and one with type 2 diabetes) and two in 
Kouvola (one with both diabetes types). They were mostly patients in dialysis therapy due to end 
stage diabetic nephropathy. Their influence on the total costs would have been significant and 
incidental without any true connection to the quality of the diabetes care in PHC.  
4.3.6 Satisfaction of type 1 diabetic patients – Study IV 
A 12-item questionnaire was used to evaluate the satisfaction of type 1 diabetic patients with 
different domains of the care (Appendix III). The questionnaire was sent to 50 randomly selected 
type 1 diabetic patients living in both study municipalities who were under the follow-up of the 
health care centres. Of the selected type 1 diabetic patients 82% in Kouvola and 86% in Nurmijärvi 
returned the questionnaire. The questionnaire was planned by the researchers and the questions 
included four alternatives, half of which were positive and half were negative. A neutral alternative 
was not available in order to get honest opinions. There was also room for free-form text. 
4.4  Statistical analyses 
All results are given as means ± SD (standard deviation). Unpaired Student´s T-test was used for 
between-group comparisons, since the variables distributed normally (study I, study II). For 
qualitative parameters, the group differences were analysed with the chi-squared test (study II, 
study IV). Pearson´s correlation coefficient was used to test the dependence between the two 
variables (study I). The independent role of the risk factors for the episodes of SH was analysed by 
using multivariate stepwise logistic regression analysis (study II). The differences between the costs 
of diabetes care as well as the mean levels of the laboratory parameters and blood pressure were 
compared using the Mann-Whitney test for two independent non-parametric samples, because the 
outcomes did not distribute normally (study IV). The Bonferroni correction was used in the analysis 
of the patient satisfaction (study IV). 
4.5 Ethics 
The contacting procedure described above was approved by the Ethics Committee of the 
Department of Internal Medicine in Helsinki Uusimaa Hospital District. The Helsinki-Uusimaa and 
Kymenlaakso Hospital Districts approved the study protocol and granted permission to collect 
clinical data from patient records and paramedic service registers.  The anonymous, crypted patient 
register information needed was used with the permission of the Finnish National Institute for 
Health and Welfare. 
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Every diabetic patient, who fulfilled the criteria to participate the study, was asked for an informed 
consent that justified their medical records at various health care organizations to be examined. In 
practice, the consent was mostly utilized to pick up the data of the use of the health centre services 
of the diabetic patients from the year 2005. The number and the mean of every patient´s diabetes-
related laboratory tests, the means of blood pressure and BMI measures, the number of visits to 
diabetes specialist nurses, physiotherapists, doctors because of the diabetes, were calculated. The 
same information was searched from the specialist level medical records of the diabetics living in 
Nurmijärvi, if they announced themselves to be in the follow-up of hospital outpatient clinics. In 
Kouvola, the same data could be gathered from the health centre because of the mutual laboratory 
data system of all levels of public health care in the region.  
35 
 
5 Results 
5.1 Demographic data of the diabetic populations studied 
The diabetic populations in both study municipalities were of similar size, 1195 in Kouvola and 1170 
in Nurmijärvi. The principal interest was focused on type 1 diabetes, which was the diagnosis of 171 
patients in Kouvola and 170 patients in Nurmijärvi in the beginning (yr. 2005) of the study (Figure 
3). Six years later, at the end of the study, these cohorts were exactly of the same size (n=165) 
because of six deaths in Kouvola and five in Nurmijärvi. In both municipalities about 40% of the 
type 1 diabetic patients were females and 60% males, and the average age was 44.1 years in 
Kouvola and 44.4 years in Nurmijärvi at the beginning of the trial. Almost all of the patients were 
Caucasians. There was no difference between the average diabetes duration in these patient 
cohorts. 
The sizes of the type 2 diabetic cohorts were much bigger but also similar in both study 
communities (n=958 in Kouvola and 932 in Nurmijärvi at the beginning of the study). Their average 
age was 66.1 years in Kouvola and 64.4 years in Nurmijärvi. Half of the patients were female both in 
Kouvola and in Nurmijärvi. 
We excluded the patients with the diagnosis of secondary diabetes and those whose diabetes type 
could not be determined. Of the original study patients 41 had an injured pancreas due to a 
previous pancreatitis, trauma or pancreatic tumour. The remaining 93 patients did not give an 
informed consent or they could not be reached at all. None of the latter had used public health care 
during the study period because of their diabetes. The vast majority of them were obviously type 2 
diabetic patients in an early phase of their disease. 
5.2 Methodological comparability of the HbA1c-determinations used – Study I 
There was a high correlation (r=0.96, p˂0.001) between the HbA1c results of the immunological 
methods of two laboratories compared. However, the levels of the HbA1c  results were significantly 
different (p<0.001) from low to high values: the results of the laboratory of Kuusankoski local 
hospital (used in Kouvola) were on the average 0.6 %-units lower than the results of  the VITA-
laboratory used in Nurmijärvi. The individual difference varied from 0.1% to 1.6%, and every single 
patient had a lower HbA1c value measured in the laboratory of Kuusankoski hospital than in the 
private VITA-laboratory. The mean difference was bigger on higher HbA1c levels (Figure 4). The 
difference of HbA1c results between the study laboratories was large enough to influence the 
clinical decision making in the treatment of diabetic patients. The number of samples analysed is 
low but even now the difference in the results is highly significant (p ˂ 0.001). 
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Figure 4.  The interlaboratory difference in HbA1c determinations according to the HbA1c level (the 
higher of the two results = the results of Nurmijärvi / VITA-laboratory). R = 0.96 
 
5.3 Comparison of the glycaemic control in the study patients – Study IV 
5.3.1 Type 1 diabetic patients 
During the study year, in the type 1 diabetic patients of Kouvola, the median and mean HbA1c was 
8.15 % and 8.16 ± 1.28 %, respectively. In Nurmijärvi, the median was 8.28 % and the mean 8.20 ± 
1.28 %. There was no statistical difference of mean HbA1c values between the type 1 diabetic 
patients living in Kouvola and Nurmijärvi, but the possible influence of methodological differences 
in the HbA1c determinations must be taken into account as presented previously. If the difference 
observed between the HbA1c assays in blood samples taken during two days would have been 
constant through the whole study year, the mean HbA1c value of type 1 diabetic patients living in 
Nurmijärvi had been significantly lower than that in type 1 diabetic patients living in Kouvola  
(p<0.01). 
The distribution of the HbA1c values of type 1 diabetic patients according to the targets defined by 
the Finnish guideline for the treatment of type 1 diabetes in the year 2005 is shown in Table 6. 
Thirty percent of type 1 diabetic patients living both in Kouvola and Nurmijärvi had good glycaemic 
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control according to the quality standards of the Finnish guideline for the care of type 1 diabetic 
patients (Table 5). 
 
Table 5.  The distribution of HbA1c values of type 1 diabetic patients according to the targets 
defined by the Finnish guideline for the treatment of type 1 diabetes in the year 2005 
HbA1c, % Meaning Kouvola Nurmijärvi 
 
< 7.0  give attention to the possibility of 
asymptomatic hypoglycaemias 
 
15.7 % 
n=17 
16.7% 
n=21 
7.0 - 7.5 good glycaemic control 
 
14.9 % 
n=16 
13.5 % 
n=17 
7,5 – 8.5 fair glycaemic control 31.4 % 
n=34 
34.1 % 
n=41 
> 8.5 consider, what should be done 
 
38.0 % 
n=40 
35.7 % 
n=45 
 
5.3.2 Type 2 diabetic patients 
The mean HbA1c values of type 2 diabetic patients living in the two municipalities did not differ 
significantly from each other (7.09 ± 1.11% in Kouvola and 7.19 ± 1.11% in Nurmijärvi) (Table 6). 
 
Table 6.  The mean HbA1c values of type 2 diabetic patients living in the two municipalities 
according to the model of care 
Treatment modality 
(% of patients) 
HbA1c, % 
 Kouvola Nurmijärvi Altogether 
 
Diet (11.7) 
 
 
6.4 ± 0.6 
n=76 
6.2 ± 0.6* 
n=75 
6.3 ± 0.6 
Oral agents (52.7) 
 
 
6.8 ± 0.9 
n=363 
6.7 ± 0.8* 
n=320 
6.8 ± 0.9 
Combination therapy (20.6) 
 
 
7.8 ± 1.1 
n=120 
7.9 ± 1.2 
n=146 
7.9 ± 1.1 
Insulin therapy (15.1) 
 
7.9 ± 1.5 
n=67 
8.1 ± 1.2 
n=128 
8.0 ± 1.3 
 
*p< 0, 05 for difference between patients living in the study municipalities 
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If the values of Kouvola are corrected upwards similarly as previously in type 1 diabetes using linear 
regression, the HbA1c values of Nurmijärvi would have been significantly lower than in Kouvola 
(p<0.001). 
5.4 Incidence and risk factors of serious hypoglycaemias in study patients – Study III  
5.4.1 Severe hypoglycaemias requiring paramedic or emergency room care 
Altogether 100 episodes of SH needing emergency health care occurred in 47 patients of whom 35 
had type 1 diabetes, 11 type 2 diabetes, and one with secondary diabetes. The incidence of SH 
needing paramedics or emergency room care was 30.5 and 1.3 per 100 patient years in patients 
with type 1 diabetes or type 2 diabetes, respectively. In type 2 diabetic patients SHs resulted in 
need of paramedics or emergency care only in 9% of SH episodes, whereas in type 1 diabetic 
patients 42 % of SH episodes needed paramedic or emergency room care. 
5.4.2 Incidence of self-reported serious hypoglycaemias 
As expected, the risk of self-reported SH in type 2 diabetic patients was much lower than in type 1 
diabetic patients (14.4 vs. 72.0 per 100 patient years, respectively). However, due to the much 
higher prevalence of type 2 diabetes, 154 (45.3 %) of all 340 SH episodes were reported by type 2 
diabetic patients. On average, type 1 diabetic patients suffered from SH once in 1.5 years, type 2 
diabetic patients with insulin treatment once in four years. Of type 1 diabetic patients 72.7% and of 
type 2 diabetic patients with insulin therapy 87.9% did not have a single episode of SH during the 
observation year (2005). SHs in diabetic patients with oral medication were rare (6.0 episodes per 
100 patient years) occurring mostly in elderly people with renal impairment. The incidence of SHs 
among type 2 diabetic patients with oral medication, diabetic nephropathy and age ≥ 70 years was 
20.0 episodes per 100 patient years approaching the risk of insulin-treated type 2 diabetic patients 
(27.0 episodes per 100 patient years). 
5.4.3 Clustering of self-reported hypoglycaemias – Study II 
The distribution of self-reported hypoglycaemias is shown in Figure 5. Self-reported SHs were highly 
clustered (three or more episodes in a year) in 53 (7.7 %) of insulin-treated patients. Thirty three 
(62.2 %) of these patients had type 1 diabetes and twenty patients had type 2 diabetes. Eleven (19 
%) patients with clustering of SH were outliers of any regular diabetes follow-up. 
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Figure 5. Clustering of self-reported hypoglycaemias  
 
5.4.4 Risk factors of severe hypoglycaemia – Study III 
The incidence of self-reported SH among diabetic patients living in two municipalities was similar 
(24.3 episodes per 100 patient years in Kouvola and 22.8 episodes per 100 patient years in 
Nurmijärvi). Of all risk factors for SH included in logistic multivariate analysis nephropathy, 
depression, physical activity and follow-up of patients in secondary or tertiary care units were 
shown to predispose the diabetic patients to SH. In this study the HbA1c value did not have any 
correlation with the number of reported SH episodes.  
5.5 Impact of recurrent serious hypoglycaemias on the validity of driver’s license – Study II 
Of all 385 insulin treated patients without any reported SH 70 % owned a valid driver’s license. 
Moreover 20% of them had a valid driver’s license for driving with heavy vehicles at least 3.5 tons 
(group 2 driver´s license). Also of the 53 insulin treated patients with the recurrent episodes of SH 
36 (68 %) had a valid driver’s license and even 11 (21 %) had a valid driver’s license for driving 
heavy motor vehicles. No one of them had been given any type of official driving restrictions due to 
severe hypoglycaemias.  
5.6 LDL-cholesterol, blood pressure and body mass index of the study patients – Study III 
The median LDL of type 1 diabetic patients living in Kouvola was 2.58 mmol/l and in Nurmijärvi 2.48 
mmol/l, respectively (Table 7). In the Finnish guidelines for type 1 diabetes at the time of the study 
the target for LDL-cholesterol was ≤3.0 mmol/l. 
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There was no difference between the medians of the blood pressure values of type 1 diabetic 
patients living in Kouvola (139/80 mmHg) and in Nurmijärvi (137/78 mmHg). Type 1 diabetic 
patients living in Kouvola had lower BMI than those living in Nurmijärvi and this difference was 
even statistically significant. The weight of 975 diabetic patients had both been reported by the 
questionnaire and measured by the personnel: the self-measured weight was on average 1.42 kg 
lower. Of type 1 diabetic patients 35.3% were daily smokers in Nurmijärvi but only 21.4% in 
Kouvola. Alcohol use was as abundant among the diabetic patients of both municipalities. 
The type 2 diabetic patients living in Kouvola had significantly lower mean and median blood 
pressure than those living in Nurmijärvi (Table 7), but there were no significant differences in LDL 
cholesterol or BMI between the type 2 diabetic patients. 
 
Table 7.   LDL-cholesterol, blood pressure and body mass index of the study patients 
Measurement Type 1 diabetes Type 2 diabetes 
 
 Kouvola 
 
Nurmijärvi 
 
Kouvola Nurmijärvi 
LDL-cholesterol 
(mmol/l) 
during the past 1.5 
years 
 
2.6 ± 0.6 
 
n=93 
2.6 ± 0.8 
 
n=112 
2.7 ± 0.8 
 
n=441 
2.6 ± 0.7 
 
n=524 
BMI (kg/m2) 
during the past year 
 
24.7 ± 3.8 
n=99 
26.3 ± 5.0* 
n=101 
30.4 ± 5.4 
n=421 
32.5 ± 6.1 
n=405 
Systolic blood pressure 
(mmHg) during the 
past year 
140 ± 19 
n=99 
140 ±18 
n=121 
144 ± 18 
n=566 
146 ±17* 
n=578 
Diastolic blood pressure 
(mmHg) during the past 
year 
80 ± 10 
n=52 
82 ± 11 
n=121 
80 ± 10 
n=565 
83 ± 10** 
n=578 
* p< 0.05, ** p<0.01 for the difference between patients living at study municipalities 
 
 
5.7 Implementation of the national guidelines for diabetes care in the study patients – Study IV 
In type 1 diabetic patients, the recommendations given in guidelines were generally better 
implemented in Nurmijärvi than in Kouvola (Table 8). The measurements recommended to be 
taken at every visit, were studied from a time period of one year. Measurements recommended to 
be included in yearly controls were studied from a time period of 1.5 years (nU-alb, foot 
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examination, LDL-cholesterol). Eye fundus photographing arranged by a private company had 
better patient coverage in Kouvola than in Nurmijärvi, where eye fundus photographs were taken 
locally. In Kouvola, a smaller proportion of type 1 diabetic patients was followed up by PHC than in 
Nurmijärvi (49.4 vs. 61.4 %). Of type 1 diabetic patients 12.4 % living in Nurmijärvi and 19.0 % living 
in Kouvola had not had any diabetes control during the previous year (Table 9). 
 
Table 8.  Coverage of diabetes care in two communities.  Only the patients who reported 
themselves to be in the follow-up of the health centres were included in the evaluation of the 
proportion of examined patients 
Measurement/ 
Examination 
Type 1 diabetes Type 2 diabetes 
 
Kouvola 
n=84 
Nurmijärvi 
n=105 
Kouvola 
n=577 
Nurmijärvi 
n=615 
 
LDL-cholesterol 
during the past 1.5 years 
 71.4    84.8*     70.0      78.5** 
BMI during the past 
year 
 51.2    77.1**     69.5**      61.3 
HbA1c during the past year 
 
 89.3    94.3     93.2      90.7 
Blood pressure during the 
past year 
 
 83.3    90.4    91.2*      87.0 
Nocturnal albumin excretion 
during the past 1.5 years 
 
 58.3    74.3**     35.2      37.1 
Eye fundus photographing 
(according to national 
guidelines) 
 
 73.8*    53.3     49.2**      35.1 
Foot examination during 
the past 1.5 years 
 
 44.0    88.0**     43.5      43.2 
*p<0.05, **p<0.01 for the difference between patients living in the study municipalities 
 
In type 2 diabetic patients HbA1c and blood pressure recordings were carried out yearly in a 
majority of patients living in the study municipalities. Weight measurement for the calculation of 
BMI was done more often in type 2 diabetic patients living in Kouvola compared with those living in 
Nurmijärvi; whereas LDL cholesterol was measured more often in type 2 diabetic patients living in 
Nurmijärvi than in Kouvola. In both municipalities, the examination of nocturnal urinary albumin 
excretion rate (or U-alb/krea) had been measured only in one third of type 2 diabetic patients 
during the past 1.5 years. Eye fundus photographing was done more often in type 2 diabetic 
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patients living in Kouvola than in Nurmijärvi, and in both municipalities it covered less than half of 
the type 2 diabetic patients. Foot examinations during the past 1.5 years covered also less than half 
of the type 2 diabetic patients (Table 8). 
 
5.8 Utilization and costs of diabetes or its complications related health care services – Study IV 
5.8.1 Use of specialist consultations and hospital beds 
As shown in Table 9 and Figures 8 and 9 both type 1 and type 2 diabetic patients living in Kouvola 
made significantly more outpatient hospital visits than those living in Nurmijärvi during the 
observation years 2005-2010.  
 
Table 9.  Use of primary or specialist care facilities, proportion of patients who had not participated 
any regular care and deaths of type 1 diabetic patients during the study years 
 Kouvola 
(n=171) 
Nurmijärvi 
(n=170) 
 
Percentage of type 1 diabetic patients who had visited 
specialist level care because of diabetes or diabetes related 
complications at least once during the years 2005-2010 
 
82.5* 67.6 
Percentage of type 1 diabetic patients being in regular 
follow-up of health care centres during the study year 2005 
 
49.4 61.4* 
Percentage of all type 1 diabetic patients who had not 
visited a doctor because of diabetes during the study year 
2005 
19.0 12.4 
Number of type 1 diabetic patients (%) who had died 
during the years 2005-2010  
 
6 (3.5 %) 5 (2.9 %) 
*p<0.05 for the difference between patients living in the study municipalities. The number of type 1 
diabetic patients in the study municipalities is given in parentheses. 
 
A slightly bigger proportion of both type 1 diabetic patients (37 vs. 33 %) and type 2 diabetic 
patients (39 vs. 36 %) from Kouvola than those from Nurmijärvi had used specialist level hospital 
beds during six study years because of their diabetes or its complications, but the difference was 
not significant. The hospital care periods of diabetic patients in Kouvola were on average shorter 
than those living in Nurmijärvi (Figures 6, 7). 
43 
 
  
Figure 6.  Average number of specialist level inpatient periods in both diabetes types during years  
2005 – 2010 in the study municipalities 
 
                      
Figure 7. Average number of specialist level inpatient days in both diabetes types during years 
2005-2010 in the study municipalities 
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5.8.2 Costs of health care services – Study IV 
The most used and nearest hospital offering specialist level care in Kouvola was the local hospital of 
Kuusankoski. Diabetic patients requiring more comprehensive care were treated in the central 
hospital of Kymenlaakso (Kotka), and only a few diabetic patients got treatment in Helsinki 
University Central Hospital. For diabetic patients living in Nurmijärvi, specialist level care was 
provided by the hospital of Hyvinkää, which has 5% higher prices of invoicing than Kuusankoski 
local hospital. Tertiary level care for patients living in Nurmijärvi was given in Helsinki University 
Central Hospital, where the prices were 10 % higher than in Kymenlaakso Central Hospital. The 
average yearly costs of specialist level outpatient care in type 1 and type 2 diabetic patients living in 
the study municipalities are shown in Figures 8 and 9.  
 
Figure 8.  The average yearly costs of specialist level outpatient care of type 1 diabetic patients in the 
study municipalities during years 2005-2010  
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Figure 9.  The average yearly costs of specialist level outpatient care of type 2 diabetic patients   of 
the study municipalities during years 2005-2010  
 
Regardless of these differences, the total health care costs of one type 2 diabetic patient during the 
years 2005 – 2010 were slightly smaller in Nurmijärvi than in Kouvola. Figures 10 and 11 summarize 
the average yearly costs per patient during the study years 2005-2010 from the use of outpatient 
and inpatient care in type 1 and type 2 diabetic patients living in the study municipalities. 
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Figure 10. Average yearly inpatient and outpatient costs of one type 1 diabetic patient in the study 
municipalities according to the health care level (years 2005-2010).  
 
 
Figure 11. Average yearly inpatient and outpatient costs of one type 2 diabetic patient in the study 
municipalities according to the health care level (years 2005—2010).  
 
 
Taken together in the both study municipalities the yearly average diabetes and diabetic 
complications related costs of health care services (discounted in the prices of year 2010) in type 1 
diabetic and type 2 diabetic patients were about 2000 and 1000 €, respectively (Figures 10 and 11). 
In the care of type 2 diabetes about half of the costs came from PHC whereas about 75 % of the 
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costs of type 1 diabetes care came from specialist level.  In type 1 diabetic patients there was a 
clear and significant difference in the costs of diabetes care between the two municipalities: the 
total yearly costs of the diabetes care of one type 1 diabetic patient were 2220 € in Kouvola and 
1710 € in Nurmijärvi calculated in the year 2010 prices. The difference was caused by the fewer 
visits of type 1 diabetic patients from Nurmijärvi to hospital outpatient clinics. On PHC level the 
yearly costs of type 1 diabetes care were very similar in both of the municipalities: 522 € in Kouvola 
and 505 € in Nurmijärvi. Inside these costs more money was spent on inpatient care in Kouvola 
than in Nurmijärvi and on outpatient care in Nurmijärvi (Figure 12). 
 
Figure 12. Total average yearly costs of diabetes care per 1 patient during years 2005-2010 in year 
2010 prices. 
 
The exceptionally expensive patients were excluded from the final analysis because of their 
incidental, but still very significant influence on the results. If these few patients  had been included 
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Kouvola (2577 € per year) and 45% higher in Nurmijärvi (2479 € per year). 
The costs of one type 2 diabetic patient were approximately half of the costs of one type 1 diabetic 
patient and about half of the costs came from PHC, the other half from specialist level care. 
However, based on the high prevalence of the disease, total costs due to the care of type 2 
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the smaller costs in PHC. In the total costs of specialist level care, there was only an average 
difference of two euro in a year (Figure 11). 
 
5.9 Satisfaction of type 1 diabetic patients with their health care services – Study IV 
Type 1 diabetic patients were quite satisfied with their follow-up and other diabetes related 
services provided by PHC in both municipalities (Figure 13). The lowest level of satisfaction was 
given to the quality of foot care provided by PHC in Kouvola, and it differed significantly from that 
organized in Nurmijärvi. Type 1 diabetic patients were also more satisfied with the professional 
skills of the doctors working in the health centre of Nurmijärvi than in Kouvola. Type 1 diabetic 
patients reported also that it was significantly easier to make a contact with the personnel of PHC 
in Nurmijärvi than in Kouvola. Taken together type 1 diabetic patients were more satisfied with the 
diabetes care in PHC of Nurmijärvi than of Kouvola. 
 
 
Figure 13.  Satisfaction of type 1 diabetic patients with different sections of the diabetes care in the 
two health care centres. *p<0.05, **p<0.01 and ***p<0.001 for difference between the satisfaction 
in the study municipalities  
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6 Discussion 
6.1 Key findings 
This study evaluates the impact of two different models of diabetes care on the quality of the 
treatment and follow-up and health care costs of diabetic patients in two municipalities with 
similar populations of diabetic patients. The main target group is the type 1 diabetic population of 
our two study municipalities. However, the care of the type 2 diabetic population was also studied. 
6.1.1 Key findings of study I 
When comparing the results of diabetes care of these different care units, the validity of the means 
of comparison is inevitably faced. The traditional measure has been the use of the HbA1c values of 
various groups of diabetic patients (111). The study I showed that HbA1c has shortnesses in this 
meaning, if the determinations have been made by different analysis methods or in different 
laboratories. The average difference of 0.6 %-units is much wider than acceptable in everyday 
clinical work. 
6.1.2 Key findings of studies II and III 
Studies II and III analysed the distribution of severe hypoglycaemias in the Finnish diabetes care. 
The vast majority of all SHs were treated outside the hospital emergency care units by paramedic 
personnel, family members or other people. When all SHs were taken into account, their incidence 
was higher than in many other previous clinical trials (69, 131). Nearly half of all SHs occurred in 
type 2 diabetic patients – mostly due to the higher prevalence of type 2 diabetes. Predisposing 
factors for SHs were active exercising, depression and complicated diabetes defined by the 
presence of diabetic nephropathy. Diabetic patients followed up by thhe hospital outpatient clinics 
had a higher risk for SHs, which was probably related to their more serious disease. HbA1c level, 
type of basal insulin (NPH vs. glargine), amount of alcohol use or living alone did not correlate to 
the incidence of SHs. There was a strong tendency to clustering of SHs to a small minority of insulin-
treated patients. These diabetic patients had valid driver´s licences as often as the whole diabetic 
population on average. This was the case even in the group 2 licences authorising driving of heavy 
vehicles. Despite recurrent SHs, one fifth of these patients had not visited a doctor because of their 
diabetes during the study year.  
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6.1.3 Key findings of study IV 
The study IV compared the quality of the care of the diabetic populations of two municipalities with 
many different indicators. The satisfaction to the professional skills of the doctors among the type 1 
diabetic patients seems to be much higher in the centralized care system. The satisfaction to the 
professional skills of the diabetes specialist nurses was, however, on a very high level in both care 
systems. The care of type 1 diabetic patients in PHC followed better the national recommendations 
in the centralized system, whereas there was not any significant difference with type 2 diabetes. 
The most important difference between these two organization models of diabetes care in PHC was 
the cost-effectiveness: the total costs of the care of type 1 diabetes and its complications were 
500€/pt/year lower in the centralized care system. The difference resulted from the lower amount 
of specialist level outpatient visits. The difference in type 2 diabetes was small (32€/pt/year) but 
not without significance, as the amount of type 2 diabetic patients is big. 
6.2 Comparison with the previous literature 
6.2.1 Reproducibility of HbA1c – Study I 
The Study I gave new data about the limitations of HbA1c determinations. A small Finnish study 
from the 1990´s already showed that there is a significant variation in the reproducibility of the 
analysis results of even the liquid chromatography methods of HbA1c determinations (132).  A 
change smaller than 0.65 %-units, could be explained by the variation inside the analysis method, 
and just the changes over 0.65 %-units were clinically significant.  After this, a lot of work has been 
done with the international standardizing of the HbA1c analysis methods (133, 134). In the daily 
clinical practice, however, the accuracy of the analysis still remains approximately the same. It has, 
however, been known that HbA1c tells only something about the average glucose level during the 
last 2-3 months, but nothing about the variation or hypoglycaemias. The ADAG-study determined 
the average glucose levels behind various HbA1c –values, but the confidence intervals were wide 
(135). This study also showed that the same average plasma glucose can produce HbA1c 6% to one 
patient and 8% to some other patient. The main reason for this phenomenon is the varying living 
time of red blood cells in the blood circulation. The longer the time, the higher HbA1c is the result. 
This is because then the patient´s red cells are longer exposed to glucose. 
Clinical situations that decrease the lifetime of red blood cells and thus cause abnormally low HbA1c 
values are haemolytic anaemia, bleeding and blood transfusions from a healthy donor. On the 
other hand, HbA1c values become incorrectly high when the medium age of red cells is abnormally 
high. Some possible reasons are iron deficiency anaemia, splenectomy, aplastic anaemia and 
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polycytemia (136). Hemoglobinopathies are not recognized by all analysis methods and may 
sometimes produce incorrect results. There are also small ethnic differences in HbA1c levels and 
elderly people usually have higher values with the same glucose levels than younger people. 
Serious renal insufficiency is a source of error to HbA1c analysis with many possible mechanisms: 
iron deficiency, haemolysis, erythropoietin deficiency and production of carbamylated HbA1c. The 
daily use of big doses of acetosalicylic acid may disturb HbA1c analyses by the formation of 
acetylated HbA1c (136-138). 
Labquality performs yearly five external quality assessment rounds for HbA1c for clinical laboratories 
in Finland and other countries. The target values of the specimen used are determined by a 
European Reference Laboratory for Glycohemoglobin -unit in Holland. The approved IFCC reference 
method for the measurement of HbA1c in human blood is published by Jeppson et al. 2003 (133). 
Both of the laboratories compared in study I participated in the quality assessment rounds of 
Labquality. 
The work with standardization has not changed the fact that certain variation between different 
analysing methods exists and must be remembered in both benchmarking and clinical work. 
Labquality does not sign over the results of a single laboratory. Marked differences between the 
levels of the results of different analysing methods are still seen.  
 
6.2.2 What is new about severe hypoglycaemias? - Studies II and III 
The studies II and III give new data about the epidemiology and risk factors of severe 
hypoglycaemias. The incidence of SHs was higher than in some previous studies both in type 1 (69, 
131) and insulin treated type 2 diabetes (67, 131, 139). This is likely due to the population-based 
study design and the high participation percent of the diabetic patients to the 36-item 
questionnaire. A few other earlier population based studies have shown quite high incidences. 
Donnelly et al. published in the year 2005 a population-based prospective hypoglycaemia trial from 
Scotland: the incidence of SHs was 1.15 events per patient per year in type 1 diabetes and 0.35 
events per patient per year in insulin-treated type 2 diabetes (140). Akram et al. (75) published a 
literature survey in the year 2006 concerning the incidence of SHs in in insulin-treated type 2 
diabetes. They found 11 studies with at least 50 patients and a follow-up period of at least six 
months. The incidence of SHs was higher in retrospective than in prospective studies and the 
variation was wide (15 - 73 events per 100 patient years).  The proportion of patients having one or 
more episodes was between 1.4 to 15%. 
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Earlier studies have shown the correlation between depression and glycaemic control in diabetes 
(141-146). In this study there was also a statistical correlation between depression and the risk of 
SH. The direction of causality remains however obscure: do SHs cause depression or does 
depression lead to labile glycaemic control and SHs ? The role of depression in diabetes still needs 
more research – is there some common metabolic background in these two conditions as 
previously suggested (147, 148)? Opposite to some other studies (149), increasing age was not a 
risk factor for SHs in this study. Instead, active exercising and complicated diabetes (indicated by 
the presence of diabetic nephropathy) seemed to be predisposing factors for SHs like in the most 
previous studies (139, 140, 149-153). The clustering of SHs to a minority of insulin treated diabetic 
patients has been observed already in some earlier studies (75). In a retrospective study from the 
year 2004 Pedersen-Bjergaard et al. reported even 130 SH episodes per 100 patient years in a 
cohort of 1076 type 1 diabetic patients. SH was reported from the preceding year by 36.7% of all 
patients and 5% of all accounted for 54% of the episodes (65).   
Already mild hypoglycaemias increase markedly the risk of accidents when driving a vehicle (91-95). 
The study III showed that the instructions concerning diabetes and driving are poorly realized in the 
follow-up of Finnish diabetic patients.  
6.2.3 Utilization and costs of diabetes care – Study IV 
The study IV compared the outcome and costs of diabetes care when it is organised either 
according to a centralized model or based on family doctors in PHC. In California, a specialized 
diabetes clinic made better short-term results than a general practice clinic in diabetes care (31), 
but in this study no cost benefit analysis was done. In the Netherlands experienced diabetes 
specialist nurses made as good short-term results in diabetes care as general practitioners (32). This 
study examined the organisations of the Finnish health care system and that is why there exist only 
a few studies with even nearly the same kind of design (115). The organizations of the health care 
systems of different countries vary and thus national research is required.  The example of Sweden 
shows the advantages of a national diabetes register in improving the quality of care (154). In North 
Carelia, a regional register system has been established and now benchmarking of the diabetes 
care between the municipalities is easier. The problematic areas can be recognized, which is the 
basis for improvements (115). 
In both of the municipalities median HbA1c values of type 1 diabetic patients were lower than in 
Valle´s studies yrs. 1993-2010 (16-18). After the year 2005 the means of HbA1c values of type 2 
diabetic patients have decreased according to Valle et al. and the Finnriski 2012 -study (155) - 
contrary to type 1 diabetes. Both these studies are based on samples of patients, which probably 
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do not represent the same kind of diabetic patients as the previous studies. This is due to the 
efficient screening of new patients, which in turn “dilutes” the study population emphasizing the 
proportion of diabetic patients in the early phases of their disease. The Finnriski 2012 study was 
based on a random sample of the population register. 59 % of the invited people took part in the 
study and the number of type 2 diabetic patients was 347. A method like this surely contains a 
possibility to a selection bias (156). In the editorial of the journal of the Finnish medical association, 
that published the Finnriski 2012 results, two leading Finnish diabetologists call for better means 
for evaluation of the quality of diabetes care (156). 
In type 2 diabetes, small but significant differences were observed in the coverage of examinations 
recommended in national guidelines for diabetes care, all of them to the advantage of Kouvola. The 
blood pressures of the type 2 diabetic patients were significantly higher in Nurmijärvi. This data can 
be compared with the data obtained from the Finnish Quality Network (FQN). The work of FQN is 
based on yearly samples of care results, benchmarking, teaching and sharing of good practices and 
ideas. In the year 2005, the mean HbA1c, LDL-cholesterol and blood pressure of type 2 diabetes in 
FQN´s data were 7.10 ± 0.042 %, 2.56 ± 0.03 mmol/l, 141.38 ± 1.41 mmHg (systolic) and 80.47 ± 
0.76 mmHg (diastolic), respectively (Klas Winell, FQN, personal information).  
 
6.3 Significance of the findings in the Finnish health care system 
6.3.1 The role of PHC in diabetes care 
The financial resources for the health services are limited and grow slower than the requirements 
of the continuously increasing proportion of old population and the modern, but expensive health 
and medical technology. It is important to study how the treatment of common diseases could be 
arranged as cost-effectively as possible.  It is important to find the best way to organize the follow-
up of diabetic patients in PHC. The organization of diabetes care fulfils the criteria, when the 
patients feel well, are satisfied with their treatment and do not develop the complications of 
diabetes. On the other hand, diabetes treatment should not produce a marked risk of 
hypoglycaemias, which in turn always cause a risk for accidents, cardiac arrhythmias and even 
sudden deaths (157-161). Hospital inpatient care and severe hypoglycaemias are both very 
expensive for the society and they correlate to complicated diabetes and long diabetes history 
(162). 
High-quality diabetes care in PHC is always comprehensive and takes care of all risk factors of 
cardiovascular diseases (108, 110). It is easier to motivate the patients to take good care of their 
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health, if they feel themselves to be well treated by the experts. Individual medical treatment plans 
are important in setting mutual targets, but they must be flexible and not too complicated.  
The diabetic complications develop slowly in the course of years and decades. High-quality care 
does not produce instant profits and investments for the quality of care will award the society with 
a long delay. Type 2 diabetes is closely related with the way of living. The health care system has an 
important role in advising people to more healthy habits including the reduction of smoking, eating 
and alcohol use as well as the increase in physical activity (163-165). However, the support of many 
other sectors of the society is also needed to get closer to these targets. 
6.3.2 HbA1c as a marker of glycaemic control 
Physicians have been used to evaluate a patient´s glycaemic control mainly by the HbA1c-value. 
Changes to the treatment are seldom made, if HbA1c is under the target value and the patient feels 
well. This laboratory parameter, however, works the best in the follow-up of a single diabetic 
patient if the analysing laboratory and the method of analysis keep the same. The glycaemic control 
between two patients cannot be compared with each other only by the HbA1c values. 
Benchmarking of the quality of diabetes care can neither be done by comparing the means of HbA1c 
values, if they are not measured with the same analysis method HbA1c does not always reflect good 
glucose balance – there may also be recurrent hypoglycaemias and a wide variation of the glucose 
concentration (166-169). The limitations of HbA1c measurement have previously been poorly 
known among the Finnish doctors, but this study has provided new insight into the use of this 
parameter in the follow-up of diabetic patients. In the future, it is important to further standardize 
HbA1c. 
6.3.3 Severe hypoglycaemias as a threat to good diabetes care 
The efforts to bring the median HbA1c values as low as possible, and the patients near to 
normoglycaemia, reveal inevitably the opposite problem: the risk of severe hypoglycaemias. Recent 
large trials like Accord and VADT carried out in patients with type 2 diabetes strongly suggest that 
recurrent severe hypoglycaemias may be harmful for the health of diabetic people. In those trials, 
however, the incidence of hypoglycaemias was the highest in the patient group with the worst 
glucose balance when estimated with HbA1c level. Hypoglycaemias increase the risk of accidents, 
expose patients to cardiac arrhythmias, and cause in the long run declining of cognitive functions 
(170-172) and even increase mortality (19, 20, 45). According to a recent study, also in patients 
with type 1 diabetes, low HbA1c values may increase the risk of all-cause mortality (174, 175). 
Alterations in ECG and lowered myocardial blood circulation have already been shown during 
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hypoglycaemic periods (176-179). Continuous monitoring of tissue glucose has shown long 
hypoglycaemic nocturnal episodes in patients, whose HbA1c is under 7 % (166). Before the time of 
the possibility to glucose monitoring, their glucose control would be appreciated as excellent.  
In this population-based retrospective study the incidence of severe hypoglycaemias was higher 
than in random controlled trials, in which the patients with the biggest risk for SHs are usually 
automatically outside the study because of the exclusion criteria (75). This group includes people 
with alcoholism, psychiatric problems or antisocial behaviour, whose ability to commit to clinical 
investigations is questionable. The risk to SHs is connected tightly also to the insulin treatment of 
type 2 diabetic people and the risk increases, if the kidney function is impaired. The incidence of SH 
is generally lower in type 2 diabetes than in type 1 diabetes, but according to our study, nearly half 
of all SHs occurred in the group of type 2 diabetic people.  However, the SHs are somewhat 
different in type 2 diabetes, because they seldom lead to calling paramedics or transportations to 
hospital emergency units. Perhaps the SHs of the younger type 1 diabetic patients more often occur 
in working places, schools, sporting areas, streets etc.  
The number of insulin treated elderly people is rapidly growing. This result is an increasing burden 
to the health care system, especially for the home care (180). It is obvious that insulin-treated 
elderly people come sooner or later to a situation, where they no more can take the responsibility 
of their own insulin treatment anymore. To solve this problem new ideas and innovations are 
needed in the near future. 
6.3.4 Influence of hypoglycaemias on driving licence eligibility 
Recurrent hypoglycaemias cluster to a small proportion of all medically treated diabetic patients. It 
would be very important to recognize these patients and to make the required changes to their 
insulin treatment or other conditions that affect their glycaemic control. The current situation in 
Finland is problematic, because the data systems of the paramedics do not communicate with the 
patient record systems of the health care providers. Moreover, the majority of SHs is treated with 
the aid of other people without any interference of the health care system. The diabetic patients 
know about the doctors´ duty to notify the traffic authorities about the impaired driving ability. In 
this evaluation, the occurrence of hypoglycaemias plays the major role, especially if the warning 
symptoms are weak or absent (95, 98). This is obviously the reason why the diabetic patients often 
hide this problem from their diabetes doctors and nurses (99). A solution for this problem could be 
a separate ´driving ability evaluation centre´ for the comprehensive estimations of driving capacity 
in borderline cases? The present situation may also jeopardize the well-functioning relation 
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between the patient and the doctor in the follow-up of the diabetes. It is, however, encouraging 
that 80 % of insulin-treated diabetic patients did not have a single SH during the study year. 
The Finnish regulations for health and follow-up demands of diabetic drivers were quite tight 
already in the year 2005 when the patient cohort for this study was collected. If the regulations 
were followed exactly, many of type 1 diabetic patients would most likely have lost their driving 
license. It is worrying that among the diabetic patients with three or more SHs during the study 
year, there were as many driver´s license holders as among the diabetic population as a whole. Is 
the reason for this in the unawareness of the doctors about the SHs of their diabetic patients or 
their unwillingness to give restrictions for driving thus jeopardizing the doctor-patient relationship 
(181)? 
6.3.5 Quality and use of primary health care services 
The Study IV compared the outcome and quality of diabetes care in PHC when organized in a 
centralized model or when based on family doctors. The quality of diabetes care in PHC determines 
the total outcome a lot. The specialist level health care has to take the responsibility of the 
examination and treatment of advanced diabetic complications.  
Only a small proportion of diabetic patients is in a proper follow-up in the private health care due 
to the expenses of the recommended laboratory testing. On the other hand, the possibilities of 
occupational health care to offer adequate diabetes care are limited. According to these facts, in 
Finland the public primary health care has the responsibility to take care of a vast majority of the 
treatment and follow-up of also type 1 diabetic patients. This includes the early diagnosis of 
developing diabetic complications in order to prevent blindness, amputations, renal failure, cardiac 
attacks, strokes etc.  
In Sweden the follow-up of type 1 diabetic patients is centralized to areal diabetes specialist 
centres and the Swedish National Diabetes Register makes it possible to do benchmarking and 
gather knowledge of the whole Swedish diabetic population (119). The average glucose control of 
type 1 diabetic patients seems to be better than in Finland (182, 183). 
If the quality of treatment in PHC is inadequate, the consequence may be an increased number of 
complications with high costs. It is also important that the follow-up system of diabetic patients 
reaches as many patients as possible. The treatment of type 1 diabetic patients in Finland is not on 
a satisfactory level and the results of care have not become better during the last decades. 
Especially in the decentralized diabetes care model in PHC a bigger proportion of type 1 diabetic 
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patients seem to have inadequate services. The dissatisfaction to the skills of the doctors produces 
more drop-outs of regular follow-up and the treatment adherence weakens. 
6.3.6 Strengths and limitations of the study 
Strength of this study is the long history of the models of organizing diabetes care in both of two 
municipalities. The target population was unselected and consisted of the whole adult-aged 
diabetic populations of these municipalities. The identification of the target population was based 
mostly on the patient lists of the public distribution points of diabetes care supplies in two 
municipalities. These lists were exceptionally well maintained in both cases. Thus the target 
population included significantly more patients than the Reimbursement Register of the Social 
Insurance Institute of Finland. Every person in the target group had some connection to the health 
centres as a diabetic patient. It is possible that a small group of people with diabetes diagnosis 
were not reached. This might theoretically be possible in the case that a diabetic patient had visited 
only the private health care or occupational health care because of the diabetes without even using 
the public diabetes supply distribution points. The diabetic patients get devices for the self-
measuring of blood glucose almost routinely at the time of diagnosis. This is the case despite 
controversial evidence of the advantages of the practise in the early phases of type 2 diabetes. The 
devices and their test strips are fetched from the public distribution points also in the case of some 
other follow-up unit. 
The participation rate of the patients was good in both study municipalities. Of all diabetic patients 
living in the study municipalities 67% gave an informed consent to use their health records and 61% 
of all returned our 36-item questionnaire considering their demographic data, lifestyle and various 
aspects of diabetes care. The use and costs of the specialist level health care could be calculated for 
all diabetic patients identified, regardless of the consent. The type 1 diabetic populations were 
same-aged in both municipalities. In type 2 diabetes there was a difference of 1.7 years in the 
average age – in Kouvola they were older. However, there was not a significant difference in the 
disease duration between the type 2 diabetic patients living in two municipalities. The duration of 
diabetes is considered more important than the age for the development of diabetic complications. 
However, there are many variables other than the organization of diabetes care in PHC that affect 
the outcome and total costs of diabetes care. The ways and traditions of clinical practice on 
specialist level may differ markedly. Incidental factors like the migration of single patients with 
complicated diabetes may also influence much to the total use of health care services in the study 
municipalities.  The effective treatment of end-stage diabetic renal disease, for instance, may 
produce extra quality-adjusted life years but the expenses are quite high. Implementation of new 
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practices like eye fundus screening, the insulin pump treatments or wide use of foot therapist visits 
can be expensive during the first years, and the possible savings come only after a delay of years. 
The strength of study I, i.e. the comparison of the results of the HbA1c determinations of the 
laboratories, was the successful testing without preceding information to the laboratories. 
However, the comparability of the results of HbA1c determinations as part of everyday routine 
analytics could be estimated only once during the study year with this arrangement. Therefore it is 
a limitation of this study that we do not know whether the differences in HbA1c determinations 
were accidental or constant. It is, however, very unlikely that the moment of the widest difference 
between the results would be found by the first checking. A reference laboratory should have been 
recruited to find out, which one of the two laboratories gave “correct values” – now it remained 
obscure. 
A significant proportion of patients with recurrent SHs would be excluded from randomised 
controlled studies (RCT) because of the assumed insufficient co-operation (184, 185). All possible 
data sources were used in order to find out the real incidence of SHs: questionnaires to all patients, 
paramedic registers, the health records of the local hospitals and the HILMO register data of the 
use of specialist level health services.  These are the main strengths of the hypoglycaemia studies II 
and III. Participation of the diabetic patients including the questionnaires was active in both 
municipalities.  However, there are also some limitations in these studies: questions about the 
timing and preceding symptoms of SHs would have been informative like an estimation of the 
amount of yearly kilometres driven by the patients. The memory of the diabetic patients may also 
be a source of error, concerning especially the patients with recurrent SHs. However, Akram et al. 
have studied the memory of diabetic patients concerning the number of SHs estimated 
prospectively or retrospectively: they noticed that the SHs of the latest year are still very well 
remembered (75). It is possible that different patients have understood the definition of SH in 
different ways. The question concerning the SHs was like this: “Have you had your blood glucose so 
low during the last 12 months, that you have needed help from other people to recover?” No / Yes, 
_ times (Appendix I). Also in some clinical trials SH has been defined differently by the need for 
parenteral glucose infusion or glucagon injection (92, 156, 166).  
The definition of depression remained somewhat superficial: the diagnosis based only on one 
question in the questionnaire or the use of antidepressant medication. At the time of data 
sampling, the recording of the diagnoses of outpatient visits was a new duty to the doctors and 
often felt as an extra burden in their clinical work. This may have been a source for inaccuracies in 
ICD-10 coding.  
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Strength of study IV was that a vast majority of all diabetic complications are treated within the 
public health care system in Finland and the use of public specialist care is archived in the HILMO 
register. In this study the quality of diabetes care was measured from many directions and by using 
several different indicators. 
The population-based design was the most significant strength in examining the production and the 
costs of services. Thus no statistical significances or standardising by age or gender is needed, like 
in sample-based studies when modelling the use and costs of services.  
A limitation to study IV is that the public PHC system of Kouvola broke down in the year 2006 and 
the PHC was taken over by a private health service company. The change in producing the PHC 
services may have influenced the results during the latest years of the follow-up. However, diabetic 
complications needing specialist level health care develop slowly during years and decades. The 
private company, however, continued the decentralized diabetes follow-up model and made strong 
efforts to show that the quality of their work is on a high level. The amounts of produced 
outpatient services in PHC during the follow-up years 2005-2010 were estimated in relation to the 
production and costs of the year 2005. Thus a change of the producer of the services did not affect 
this part of the results.  
The structure of the specialist level services in our two municipalities differed: the nearest and 
most commonly consulted hospital of Kouvola had 5% lower prices of invoicing than the nearest 
supporting hospital of Nurmijärvi, the hospital of Hyvinkää.  The most demanding treatments of 
Kouvola were usually given in the central hospital of Kymenlaakso, which in turn had the same 
invoicing prices as the hospital of Hyvinkää. The patients of Kouvola were treated in the University 
Hospital of Helsinki only with exceptional needs, whereas the most serious cases of Nurmijärvi 
were routinely treated in the university hospital. Because of these structural features, the use of 
specialist level care became 5-10% more expensive for Nurmijärvi than for Kouvola.  On the other 
hand, this may have lowered the threshold to specialist level consultations in Kouvola. During the 
years 2006 to 2010 there was a diagnosis number for every specialist level outpatient visit and 
inpatient period in the HILMO-register and the DRG-prices could be calculated. Every diagnosis 
code is surely not exactly the right one, but all of our patients had some type of diabetes. In the 
first year of the study, there were also some outpatient visits on specialist level without any 
diagnosis. Most of these visits had been made by patients living in Kouvola (648 outpatient visits or 
17.7% of the total of 2465 visits to the specialities possibly concerned in the year 2005). The same 
proportion in Nurmijärvi was 5.4%. Approximately one third of these visits may have been done 
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due to diabetes or its complications. They were excluded from the calculations, but compared with 
all visits during six study years their proportion was small.                                                            
6.3.6 Which model of diabetes care is better? 
In type 1 diabetes the centralized care model reaches a bigger proportion of the patients, who are 
more satisfied with their treatment than in the decentralized system. Moreover, the centralized 
care model diminishes the amount of the use and costs of specialist level health care. The influence 
of the centralized care model to the total costs of the health care of type 1 diabetic patients is 
strongly positive. In type 2 diabetes the difference is small but parallel, not without significance 
because of the high prevalence of the disease. The costs and quality of the supporting services like 
eye fundus photographing and foot care depend on the local arrangements, not on the follow-up 
model per se. 
This study was based on a situation where two municipalities, with different diabetes care models 
already over 15 years, were identified. Moreover, the populations (and the diabetic populations) of 
the municipalities were almost as big and resembled each other in demographic features. The adult 
diabetic patient populations were followed as cohorts for a time interval of 6 years in order to get 
stronger results. Some sources of error are still remaining in a study design like this, but we, 
however, believe that the results are reliable. 
The superior satisfaction with the centralized care model among the type 1 diabetic patients was a 
significant and clear result. Dissatisfaction with the skills of the doctors in Kouvola was emphasized 
in the informal written answers: several patients wrote that they felt they knew more of their 
disease themselves than their doctor. The satisfaction to the foot care was very much bigger in 
Nurmijärvi, depending naturally on the fact that there was a foot therapist in Nurmijärvi but not in 
Kouvola. The satisfaction to the work of the diabetes specialist nurses was on a very high level in 
both municipalities. This may mostly be due to the personal characteristics of these much 
appreciated people in both of the municipalities. Moreover, there was no difference in the 
satisfaction to the supporting services like eye fundus photographing, diabetes supplies distribution 
or laboratory services.  
The regular follow-up of type 1 diabetic patients, according to the recommendations of existing 
Finnish guidelines, worked better in Nurmijärvi than in Kouvola. On the contrary, there were not so 
marked differences in the follow-up of type 2 diabetic patients, who actually were mostly under the 
care of family doctors in both municipalities. In Kouvola, the eye fundus photographing was done 
by a private company, which had developed an invitation system leading to better coverage. In 
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both municipalities the determination of nocturnal albuminuria was taken from fewer than 40 % of 
all type 2 diabetic patients – thus not reaching the targets. A very important part of the 
examination of a diabetic patient is to check the condition of the feet, at least once a year. Even 
this was neglected more often than in 50 % of the patients. Foot examination had been done 
properly only in type 1 diabetic patients living in Nurmijärvi. Regular foot examination is important 
also in the diagnosing of the diabetic neuropathy, since the diagnosis in PHC is mostly based on the 
abnormal findings of the feet. 
It is difficult to find the reason for the high prevalence of smoking in type 1 diabetic patients in 
Nurmijärvi; the proportion of smokers is clearly higher than in the average population [16.5% in a 
population with similar age and gender distribution (186)] and also higher than in Kouvola. In every 
case, smoking seems to be a problem that needs special attention in the future follow-up of type 1 
diabetes. 
In the centralized diabetes care system of Nurmijärvi, a bigger proportion of type 1 diabetic 
patients was followed-up in PHC and there were fewer patients who were drop-outs of the regular 
follow-up.  
Taken together, concerning to type 1 diabetic patients, the centralized care model in PHC seems to 
work better than the decentralized model but both models are equally good in the care of type 2 
diabetic patients. 
6.3.7  Centralizing produces savings 
The very expensive patients with total costs above 100 000 € during six study years were excluded 
from the comparison of health care costs.  At least the majority of these six type 1 diabetic patients 
with nephropathy had not previously been in the follow-up of the local PHC. Four of these 
expensive patients lived in Nurmijärvi and two in Kouvola.  
The outpatient specialist care in type 1 diabetes was 38.3 % cheaper per one patient and 14.3 % 
cheaper in type 2 diabetes in Nurmijärvi than in Kouvola. The costs of one type 1 diabetic patient in 
outpatient specialist care were more than four times higher than the costs of one type 2 diabetic 
patient. The specialist level inpatient periods of Kouvola were somewhat shorter in both diabetes 
types. The total yearly costs of the treatment of diabetes and its complications per one diabetic 
patient were 510 € lower in type 1 and 32 € lower in type 2 diabetes in Nurmijärvi with the 
centralized care system than in Kouvola with the decentralized care. The difference in type 2 
diabetes is small when calculated per one patient but considering the higher prevalence of type 2 
diabetes, the total sum becomes significant. Altogether, the centralized diabetes care model of 
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Nurmijärvi seemed to produce yearly cost saving of 116 500 € when compared with the family 
doctor based follow-up system of Kouvola. 
The savings produced by the centralized follow-up system of type 1 diabetes are nearly equivalent 
to the yearly costs of one general practitioner. If extrapolated to the whole country, the centralized 
follow-up of type 1 diabetic patients could produce savings of more than 10 million euro per year. 
The saved money can, of course, be used in many ways: recruiting of a new doctor can produce 
extra savings in the long run, but that is uncertain. A marked proportion of the savings can be lost 
by unsuccessful decisions. The very expensive patients with total costs above 100 000 € during the 
six study years were decided to be excluded from the comparison of health care costs.  At least the 
majority of these six type 1 diabetic patients with nephropathy had not been previously in the 
follow-up of the local PHC. Four of these expensive patients lived in Nurmijärvi and two in Kouvola.  
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7 Summary and conclusions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 HbA1c is not a good measure in comparing the quality of diabetes care of different care units, 
especially if the analyses have not been done by the same analysis method in the same 
laboratory. Moreover, HbA1c does not detect hypoglycaemias or glucose variability. 
 Almost half of all severe hypoglycaemias are suffered by type 2 diabetic patients. On average, 
type 1 diabetic patients suffer from severe hypoglycaemia once in 1.5 years and insulin-treated 
type 2 diabetic patients once in 4 years. Only the top of an iceberg is seen in the health care 
system, because most of all severe hypoglycaemias are treated at home or outside the 
hospitals by paramedics. 
 Depressive symptoms, physical activity and diagnosed diabetic nephropathy correlate with the 
risk of severe hypoglycaemias – but not the level of HbA1c, use of alcohol or the type of basal 
insulin (glargine vs. NPH). Eighty per cent of all insulin-treated diabetic patients do not have 
severe hypoglycaemias. Hypoglycaemias cluster to a small minority of all diabetic patients. 
 Patients with recurrent severe hypoglycaemias have valid driver´s licenses as frequently as the 
whole diabetic population on average. Many of them are outliers of the public diabetes care 
system having no visits to the health care system. 
 The centralized diabetes follow-up model in PHC produces significant savings in the care of 
type 1 diabetes and smaller savings in the care of type 2 diabetes. The difference is mostly due 
to more frequent consultations of specialist level outpatient health services in the 
decentralized care model.  
 Type 1 diabetic patients are more satisfied with the centralized follow-up system. The 
difference is especially notable in the satisfaction with the skills of doctors. The trust to the 
skills of diabetes specialist nurses is high in both models.  
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Conclusions 
 Modern patients need high-quality care also in the PHC. This is difficult to offer, if every doctor 
tries to be expert in all specialities. It seems to be also economically sensible to share the work 
of the doctors in the PHC according to their special interests. 
 The satisfaction inquiry confirms the old idea that the diabetes specialist nurses are a corner 
stone of diabetes care. Every type 1 diabetic patient should have an easy way to consult a 
diabetes specialist nurse. 
 An independent ´driving ability centre´ system should be established for problematic driving 
permission estimations. 
 Benchmarking of the quality of diabetes care needs new indicators, computerized data 
collection systems and national diabetes registers. 
 The connection between diabetes and depression is worth more research. 
 Avoidance of severe hypoglycaemias should be one of the main targets in diabetes care. 
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Appendix I 
 
ARVOISA TUTKIMUSHENKILÖ 
 
Saamassanne potilastiedotteessa kuvattuun tutkimukseen liittyen keräämme oheisella 
kyselykaavakkeella taustatietoja, joiden toivomme täydentävän sairaskertomustiedoissanne 
mahdollisesti esiintyviä puutteita koskien diabeteksenne hoitoon keskeisesti liittyviä asioita. 
Saamiamme vastauksia käytämme hyväksi myös, kun selvitämme, millaiset asiat liittyvät 
diabeetikkojen hoitotasapainojen eroihin. 
 
Toivomme Teidän suhtautuvan kyselyyn myönteisesti; aikaa vastaamiseen kulunee 10-15 
min. Täytetyn kaavakkeen sekä allekirjoitetun suostumuslomakkeen voitte palauttaa 
terveyskeskuksen diabeteshoitajalle, tarvikejakeluun tai myöhemmin postitse 
palautuskuoressa, jonka postimaksu on maksettu. Vaikka ette haluaisikaan vastata kyselyyn, 
voitte allekirjoittaa suostumuslomakkeen, jolloin annatte luvan diabetestietojenne 
keräämiseen tutkimusta varten. Kaikki antamanne tiedot käsitellään ehdottoman 
luottamuksellisesti ja tulokset julkaistaan muodossa, jossa kenenkään henkilökohtaisia 
tietoja ei voida jäljittää. 
 
 
VASTAUSLOMAKE 2005 
 
Tutkimuskeskuksen koodi:  I__I__I 
Potilaan koodinumero:  I__I__I__I__I 
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1. Siviilisääty 
 
1 naimisissa tai avoliitossa 
2 naimaton 
3 asumuserossa tai eronnut 
4 leski 
 
2. Millaista työtä teette suurimman osan vuodesta 
 
1 maanviljelys, karjanhoito, metsätyö, emäntä 
2 tehdas-, kaivos-, rakennus tai muu vastaava työ 
3 toimistotyö, henkinen työ, palvelutyö 
4 opiskelu tai koulunkäynti 
5 kotirouva, kotiäiti, koti-isä 
6 eläkeläinen 
7 työtön 
 
3. Mikä on ammattinne? 
                 
          _______________________________ 
 
4. Kuinka monta henkeä kuuluu kotitalouteenne tällä hetkellä Teidät itsenne mukaan 
lukien? 
 
          I__I__I  jäsentä 
 
5. Kuinka moni kotitalouteenne kuuluvista on: 
        
1 alle 7-vuotiaita?          _________ 
2 7-17 -vuotiaita?           _________ 
3 18-24 -vuotiaita?         _________ 
4 25-64 -vuotiaita?         _________ 
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6. Mikä on asumismuotonne? 
 
1 kerrostalo 
2 rivitalo / paritalo 
3 omakotitalo 
4 palveluasunto 
5 laitos (vanhainkoti, vuodeosasto) 
 
7. Arvioikaa mahdollisimman tarkasti, milloin diabeteksenne on todettu? (esim. 
kuukausi ja vuosi, pelkkä vuosi tai vuosikymmen, jos ette muista tarkemmin) 
 
  _____________________________________ 
 
8. Mikä on diabeteksenne pääasiallinen hoitopaikka? ( esim. sairaala, terveyskeskus, 
työterveyshuollon yksikkö tai yksityinen lääkäriasema; nimeltä mainiten) 
 
   
 ______________________________________________________ 
 
9. Miten pitkään diabeteksenne hoito ja seuranta on toteutettu nykyisessä hoitopaikassa? 
 
1 alle 1 vuoden ajan 
2 1-3 vuoden ajan 
3 3-5 vuoden ajan 
4 5-10 vuoden ajan 
5 yli 10 vuoden ajan 
 
10. Arvioikaa mahdollisimman tarkasti, milloin olette viimeksi käynyt silmälääkärin 
vastaanotolla tai milloin silmänpohjanne on viimeksi valokuvattu? 
 
               ____________________________________ 
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11. Onko ammattihenkilö tutkinut jalkanne viimeksi kuluneen vuoden aikana (lääkäri, 
diabeteshoitaja, muu sairaanhoitaja tai jalkojenhoitaja)? 
 
1 ei ole 
2 on 
 
12. Mikäli diabeteksenne pääasiallinen seuranta toteutuu terveyskeskuksessa tai 
sairaalassa, oletteko lisäksi käyttänyt yksityislääkärin palveluita diabeteksenne 
hoitoon liittyvissä asioissa viimeisten 12 kk:n aikana (ei koske silmälääkärillä 
käyntejä)? 
 
1 en ole 
2 olen, 1 kerran 
3 olen, 2 kertaa tai enemmän 
 
13. Oletteko viimeisten 12 kuukauden aikana käynyt jalkojenhoitajalla omalla 
kustannuksellanne? 
 
1 en ole 
2 olen, 1 kerran 
3 olen, 2 kertaa tai useammin 
 
14. Onko Teillä käytössä pieni päivittäinen asetosalisylaattilääkitys verenkiertohäiriöiden 
estoon (Aspirin, Disperin tai Primaspan 50-250mg/vrk)? 
 
1 ei ole 
2 on 
 
15. Mikäli Teillä on ns. aikuistyypin diabetes (tyyppi II) ettekä käytä 
asetosalisylaattilääkitystä, mikä on lääkkeen käyttämättömyyteen syynä? 
                  
1 allergia asetosalisyylihapolle 
2 herkkä vatsa tai esim. sairastettu vatsahaava 
3 muun verenohennuslääkityksen (esim. Marevan tai Plavix) käyttö 
4 todettu herkkyys verenvuodoille 
5 korkea ikä 
6 runsas muu lääkehoito 
7 terveydenhuoltohenkilöstö ei ole sen käyttöä suositellut 
8 en ole itse halunnut käyttää sitä, vaikka sitä on minulle suositeltu 
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16. Onko Teillä viimeeksi kuluneiden 12 kk:n aikana ollut niin matalia verensokereita 
(insuliinisokkeja), että olette joutunut turvautumaan toisen henkilön apuun? 
 
1 ei ole 
2 kyllä,  ______  kertaa 
 
17. Tupakoitteko? 
               
1 en ole koskaan polttanut (siirtykää kohtaan 12) 
2 en, lopetin ________ vuotta sitten 
3 kyllä, satunnaisesti 
4 kyllä, 1-10 savuketta vrk:ssa 
5 kyllä, 11-20 savuketta vrk:ssa 
6 kyllä, 20-30 savuketta vrk:ssa 
7 kyllä, yli 30 savuketta vrk:ssa 
8 kyllä, mutta poltan sikareita, piippua, itsekäärittyjä sätkiä tai nuuskaan 
(alleviivaa sopiva vaihtoehto) 
 
18. Arvioikaa mahdollisimman tarkasti, kuinka monen vuoden ajan elämänne aikana 
olette yhteensä tupakoinut päivittäin? 
 
   ____________________ 
 
19. Oletteko viimeksi kuluneiden 12 kk:n aikana käyttänyt mitään alkoholijuomia? 
 
1 en 
2 kyllä 
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20. Montako lasillista (tavallista ravintola-annosta) tai pullollista olette juonut edeltävän 
viikon (7 vrk) aikana seuraavia: 
Ellette ole juonut yhtään, merkitkää 0. 
  Olutta (III tai IV)   I__I__I        pullollista (1/3 l) 
   Long drink –juomia  I__I__I         pullollista (1/3 l) 
           Väkevää alkoholia  I__I__I        ravintola-annosta 
           Viiniä tai vastaavaa  I__I__I        lasillista 
  (alkoholipit. yli 5%) 
       Siideriä tai kevytviiniä  I__I__I         lasillista 
 (alkoholipit. n. 5%) 
 
21. Edellisessä vastauksessa kuvailitte alkoholin käyttönne viimeksi kuluneen viikon 
aikana. Käytättekö tavallisesti alkoholia tuohon viikkoon verrattuna 
 
1 selvästi vähemmän? 
2 hiukan vähemmän? 
3 suunnilleen saman verran? 
4 hiukan enemmän? 
5 selvästi enemmän? 
 
22. Mitä ajattelette omien ruokailutottumustenne terveellisyydestä? Syöttekö mielestänne 
 
1 erittäin terveellisesti 
2 melko terveellisesti 
3 hieman epäterveellisesti 
4 erittäin epäterveellisesti 
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23. Onko joku viimeksi kuluneiden 12 kk:n aikana kehottanut Teitä muuttamaan 
ruokailutottumuksianne terveyssyistä? 
 
1 kyllä, lääkäri 
2 kyllä, diabeteshoitaja 
3 kyllä, muu terveydenhuoltohenkilö 
4 kyllä, perheenjäsen 
5 kyllä, joku muu 
6 ei kukaan 
 
24. Pyrittekö rajoittamaan ns. kovien rasvojen (eläin- ja maitorasvat) käyttöä 
ruokavaliossanne? 
 
1 kyllä 
2 ei 
 
25. Pyrittekö tietoisesti runsaaseen kuitujen määrään (hedelmät, vihannekset ja 
kokojyväviljatuotteet) ruokavaliossanne? 
 
1 kyllä 
2 ei 
                 
26. Miten usein lisäätte suolaa ruokaanne pöydässä? 
 
1 en juuri koskaan 
2 yleensä silloin, kun ruoka ei maistu riittävän suolaiselta 
3 jokseenkin aina ennen maistamista 
 
27. Painatteko mielestänne 
 
1 huomattavasti liian paljon? 
2 jonkin verran liian paljon? 
3 hiukan liian paljon? 
4 sopivasti? 
5 liian vähän? 
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28. Oletteko pyrkinyt pudottamaan painoanne viimeksi kuluneiden 12 kk:n aikana? 
 
1 kyllä 
2 ei 
 
29. Kuinka usein harrastatte vapaa-ajan liikuntaa vähintään puoli tuntia niin, että ainakin 
lievästi hengästytte ja hikoilette? 
 
1 päivittäin 
2 4 – 6 kertaa viikossa 
3 2 – 3 kertaa viikossa 
4 viikottain - kuukausittain 
5 muutaman kerran vuodessa tai harvemmin 
6 en voi vamman tai sairauden takia harrastaa liikuntaa 
 
30. Miten rasittavaa työnne on ruumiillisesti? Valitkaa tilanteeseenne parhaiten sopiva 
vaihtoehto. Jos ette tee työtä, merkitkää 1. 
 
1 työni on pääasiassa istumatyötä enkä kävele paljonkaan 
2 kävelen työssäni melko paljon, mutta en joudu nostelemaan tai kantamaan 
raskaita esineitä 
3 joudun työssäni kävelemään ja nostelemaan paljon tai nousemaan portaita tai 
ylämäkeä 
4 työni on raskasta ruumiillista työtä, jossa joudun nostamaan tai kantamaan 
raskaita esineitä, kaivamaan, lapioimaan tai hakkaamaan jne. 
         
31. Kuinka monta minuuttia kävelette tai pyöräilette työmatkoillanne (yhteensä meno- ja 
paluumatkalla)? 
 
1 en ole työssä tai työni on kotona 
2 kuljen työmatkan kokonaan moottoriajoneuvolla 
3 alle 15min. päivässä 
4 15 – 30 min päivässä 
5 30 – 60 min päivässä 
6 yli tunnin päivässä 
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32. Oletteko tuntenut itsenne jännittyneeksi, stressaantuneeksi tai kovan paineen alaiseksi 
viimeksi kuluneen vuoden aikana? 
 
1 kyllä - elämäntilanteeni on miltei sietämätön 
2 kyllä - melkoisesti enemmän kuin ihmiset yleensä 
3 kyllä - jonkin verran mutta en käsittääkseni enempää kuin ihmiset yleensä 
4 en ollenkaan 
 
33.  Oletteko tuntenut itsenne masentuneeksi viimeksi kuluneen vuoden aikana? 
                 
1 koko ajan 
2 suurimman osan aikaa 
3 huomattavan osan aikaa 
4 jonkin aikaa 
5 vähän aikaa 
6 en ollenkaan 
       
34. Häiritseekö jokin asia elämäntilanteessanne (huolet, muut sairaudet tms.)  oleellisesti 
mahdollisuuksianne keskittyä diabeteksenne hoitoon? 
 
1 kyllä 
2 ei 
 
35.  Onko oma terveydentilanne tällä hetkellä mielestänne? 
1      hyvä 
2      melko hyvä 
3      ei hyvä eikä huono 
4      melko huono 
5      huono 
    
36.  Mikä on pituutenne? 
              I__I__I__I  cm 
1      nyt tai vastikään mitattu 
2      vanha tieto tai muistikuva 
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       ja paljonko painatte? 
  I__I__I__I  kg 
1 nyt tai vastikään punnittu 
2 arvioitu 
 
 
Merkitkää vielä päivämäärä, jona täytitte kaavakkeen:  _____ / _____   200__   ja  
tarkistakaa, että olette vastannut kaikkiin kysymyksiin. 
  
 
KIITOS VAIVANNÄÖSTÄNNE! 
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Appendix II 
        
List of the ICD-10 diagnoses and procedures which were evaluated to be diabetes-related in 
the study IV: 
 
I20-I25  
I63-66, I69 
I70-71, I74, I 80, I83.0 
J00-J15, J20, J 22 
E10-14, E65-68 
F01  
G63.2  
H28*E10-14 
H33-36  
H43        
L00-08  
L92 
M14*E10-14 
M68, M75.0, G56.0 
N17-19, N30, N10 
 
Procedures; 
ACB51, CKC10-50, CKD60-65, CKD91-95, XCD20, XCK10, FN, FWC00, FX_2 - FX_4, NFQ, NGQ, 
NGW10, NGS20, NGS99, NHQ, NHS, NHW10, PAF, PAH, PAQ, PAR, PA_, PDF, PDG, PDH, PDN, 
PDP, PDQ, PD_2, PD_3, PEF, PEG, PEH, PEN, PEP, PEQ, PER, PEU, PEW, PE1AT, PE1BT, PFH, PFP, 
PFQ, PFR, PFU, PF_, PG, PWC00, QDG, QWC00, QXG 
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Appendix III 
  
HYVÄ DIABEETIKKO! 
 
Olette antanut suostumuksen osallistumisellenne tutkimukseen, jossa vertaillaan kahden erilaisen 
hoitomallin toimivuutta diabeetikkojen hoidossa. Olette ilmoittanut diabeteksenne pääasialliseksi 
hoitopaikaksi terveyskeskuksen. Pyydämme nyt Teitä vastaamaan oheiseen 
potilastyytyväisyyskyselyyn, jollaisen olemme lähettäneet samanaikaisesti 50:lle satunnaisesti 
valitulle terveyskeskuksen hoidossa olevalle I-tyypin diabeetikolle sekä Kouvolassa että 
Nurmijärvellä. Vastatessanne pyydämme Teitä kiinnittämään huomiotanne erityisesti diabeteksenne 
hoitopalveluihin terveyskeskuksessanne. Ympäröikää vastausvaihtoehdoista kunkin kysymyksen 
kohdalla mielestänne parhaiten sopiva vaihtoehto.  Kaikkiin kysymyksiin vastattuanne palauttakaa 
kaavake oheisessa vastauskuoressa, jonka postimaksu on maksettu. 
 
Kysely on täysin luottamuksellinen eivätkä vastauksenne tule yksilöitävässä muodossa edes 
tutkimusta tekevien henkilöiden tietoon.  Tutkimuskeskuksen koodi 02 tarkoittaa Kouvolan ja 03 
Nurmijärven terveyskeskusta. Palautuskuoressa olevan koodinumeron avulla avustaja, joka ei lue 
vastauksia, voi lähettää Teille muistutuskyselyn, mikäli olette unohtanut palauttaa vastauskuoren. 
Toivomme Teidän suhtautuvan kyselyymme myönteisesti, jotta tuloksista saadaan mahdollisimman 
kattavat. Aikaa kysely täyttämiseen kulunee vain muutamia minuutteja. 
 
Kysymykset: 
       
1. Miten tyytyväinen olette diabeetikkojen hoitotarvikkeiden (neulat, verensokerin 
määritysliuskat yms.) jakelun toimivuuteen terveyskeskuksessanne? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön  
4 erittäin tyytymätön 
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2. Miten tyytyväinen olette laboratoriopalveluiden toimivuuteen terveyskeskuksessanne? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
3. Miten tyytyväinen olette diabeetikkojen silmätutkimusten toimivuuteen 
terveyskeskuksessanne? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
4. Miten tyytyväinen olette diabeetikkojen jalkojen tutkimiseen ja hoitoon 
terveyskeskuksessanne? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
5. Miten tyytyväinen olette saamaanne ravitsemusneuvontaan terveyskeskuksessanne? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
6. Miten tyytyväinen olette diabeteshoitajanne tavoitettavuuteen? 
  
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
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7. Miten tyytyväinen olette diabeteshoitajanne ammattitaitoon? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
8. Miten tyytyväinen olette lääkärinne tavoitettavuuteen? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
9. Miten tyytyväinen olette lääkärinne ammattitaitoon diabeteksenne hoitoa koskevissa 
asioissa? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
10. Miten tyytyväinen katsoisitte kaiken kaikkiaan olevanne diabeteksenne ja siihen 
liittyvien asioiden hoitoon terveyskeskuksessanne? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
11. Miten hyvin olette mielestänne tarvittaessa päässyt erikoissairaanhoidon arvioon 
diabeteksenne tai sen liitännäissairauksien hoitoon liittyvissä asioissa? 
 
1 erittäin hyvin 
2 melko hyvin 
3 melko huonosti 
4 erittäin huonosti 
5 en koe diabetekseni hoidon vaatineen erikoissairaanhoidon palveluita 
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12. Vielä toivoisimme teidän arvioivan, miten tyytyväinen olette omaan panokseenne 
diabeteksenne hoidossa? 
 
1 erittäin tyytyväinen 
2 melko tyytyväinen 
3 melko tyytymätön 
4 erittäin tyytymätön 
 
13. Lopuksi Teillä on mahdollisuus sanallisesti kertoa, mihin olette diabeteksenne hoidossa 
tyytymätön (tai tyytyväinen). Tutkimuksen keskeisenä tavoitteena on luonnollisesti 
kehittää diabeteksen hoitoa maassamme, jolloin potilailta saatava palaute on 
ensiarvoisen tärkeää. 
 
 
 
 
KIITOS VAIVANNÄÖSTÄNNE! 
  
      
 
 
 
 
 
               
     
 
 
           
